PKACG
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A6ND36 | S610 | Sugiyama | FAM83G PAWS1 | LSDQDSHSGSSGRGPGPRRPsVAssVsEEyFEVREHSVPLR |
| O60841 | S107 | Sugiyama | EIF5B IF2 KIAA0741 | NEEEFtsKDKKKKGQKGKKQsFDDNDsEELEDKDsKSKKTA |
| O94763 | S372 | Sugiyama | URI1 C19orf2 NNX3 PPP1R19 RMP URI | KNTTLKFSEKKEEAKRKRKNstGsGHsAQELPTIRTPADIY |
| P04075 | S46 | Sugiyama | ALDOA ALDA | PGKGILAADEstGsIAKRLQsIGtENtEENRRFyRQLLLtA |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P09923 | S111 | Sugiyama | ALPI | DRFPYLALSKTYNVDRQVPDsAATATAYLCGVKANFQTIGL |
| P10412 | S36 | Sugiyama | H1-4 H1F4 HIST1H1E | EKtPVKKKARKsAGAAKRKAsGPPVsELItKAVAASKERsG |
| P13639 | S23 | Sugiyama | EEF2 EF2 | NFtVDQIRAIMDKKANIRNMsVIAHVDHGKStLtDsLVCKA |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P14314 | S126 | Sugiyama | PRKCSH G19P1 | yNsGVICENtCKEKGRKEREsLQQMAEVtREGFRLKKILIE |
| P16402 | S37 | Sugiyama | H1-3 H1F3 HIST1H1D | KtPVKKKAKKAGATAGKRKAsGPPVsELItKAVAASKERsG |
| P16403 | S36 | Sugiyama | H1-2 H1F2 HIST1H1C | EKAPVKKKAAKKAGGtPRKAsGPPVsELItKAVAASKERsG |
| P17612 | S213 | Sugiyama | PRKACA PKACA | KGRtWtLCGtPEYLAPEIILsKGYNKAVDWWALGVLIYEMA |
| P17612 | T196 | Sugiyama | PRKACA PKACA | DQQGYIQVTDFGFAKRVKGRtWtLCGtPEYLAPEIILsKGY |
| P17612 | T198 | Sugiyama | PRKACA PKACA | QGYIQVTDFGFAKRVKGRtWtLCGtPEYLAPEIILsKGYNK |
| P17612 | T202 | Sugiyama | PRKACA PKACA | QVTDFGFAKRVKGRtWtLCGtPEYLAPEIILsKGYNKAVDW |
| P22059 | S190 | Sugiyama | OSBP OSBP1 | QRWVTALELAKAKAVKMLAEsDEsGDEEsVsQtDKTELQNT |
| P22059 | S193 | Sugiyama | OSBP OSBP1 | VTALELAKAKAVKMLAEsDEsGDEEsVsQtDKTELQNTLRT |
| P22612 | S15 | Sugiyama | PRKACG | ______MGNAPAKKDtEQEEsVNEFLAKARGDFLYRWGNPA |
| P22612 | S213 | Sugiyama | PRKACG | KGRtWtLCGtPEYLAPEIILsKGYNKAVDWWALGVLIYEMA |
| P22612 | S40 | Sugiyama | PRKACG | LAKARGDFLYRWGNPAQNTAssDQFERLRtLGMGsFGRVML |
| P22612 | S41 | Sugiyama | PRKACG | AKARGDFLYRWGNPAQNTAssDQFERLRtLGMGsFGRVMLV |
| P22612 | S54 | Sugiyama | PRKACG | PAQNTAssDQFERLRtLGMGsFGRVMLVRHQETGGHYAMKI |
| P22612 | T10 | Sugiyama | PRKACG | ___________MGNAPAKKDtEQEEsVNEFLAKARGDFLYR |
| P22612 | T196 | Sugiyama | PRKACG | DQQGYLQVTDFGFAKRVKGRtWtLCGtPEYLAPEIILsKGY |
| P22612 | T198 | Sugiyama | PRKACG | QGYLQVTDFGFAKRVKGRtWtLCGtPEYLAPEIILsKGYNK |
| P22612 | T202 | Sugiyama | PRKACG | QVTDFGFAKRVKGRtWtLCGtPEYLAPEIILsKGYNKAVDW |
| P22612 | T49 | Sugiyama | PRKACG | YRWGNPAQNTAssDQFERLRtLGMGsFGRVMLVRHQETGGH |
| P22694 | S213 | Sugiyama | PRKACB | KGRtWtLCGtPEYLAPEIILsKGYNKAVDWWALGVLIYEMA |
| P22694 | T196 | Sugiyama | PRKACB | DHQGYIQVTDFGFAKRVKGRtWtLCGtPEYLAPEIILsKGY |
| P22694 | T198 | Sugiyama | PRKACB | QGYIQVTDFGFAKRVKGRtWtLCGtPEYLAPEIILsKGYNK |
| P22694 | T202 | Sugiyama | PRKACB | QVTDFGFAKRVKGRtWtLCGtPEYLAPEIILsKGYNKAVDW |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P29474 | S1177 | SIGNOR | NOS3 | EDIFGLTLRTQEVTSRIRtQsFsLQERQLRGAVPWAFDPPG |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P46776 | S68 | Sugiyama | RPL27A | yHPGyFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRV |
| P47712 | S724 | Sugiyama | PLA2G4A CPLA2 PLA2G4 | NIDVIKEAMVESIEyRRQNPsRCsVsLsNVEARRFFNKEFL |
| P51116 | S601 | Sugiyama | FXR2 FMR1L2 | RPQRRNRSRRRRNRGNRtDGsIsGDRQPVtVADyIsRAEsQ |
| P60709 | S199 | Sugiyama | ACTB | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P60709 | S52 | Sugiyama | ACTB | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P62273 | Y7 | Sugiyama | RPS29 | ______________MGHQQLyWsHPRKFGQGSRSCRVCSNR |
| P62736 | S54 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P63261 | S199 | Sugiyama | ACTG1 ACTG | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P63261 | S52 | Sugiyama | ACTG1 ACTG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P63267 | S53 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68032 | S54 | Sugiyama | ACTC1 ACTC | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68133 | S54 | Sugiyama | ACTA1 ACTA | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| Q02543 | S123 | Sugiyama | RPL18A | AGAVtQCyRDMGARHRARAHsIQIMKVEEIAASKCRRPAVK |
| Q09161 | S22 | Sugiyama | NCBP1 CBP80 NCBP | SRRRHsDENDGGQPHKRRKtsDANEtEDHLEsLICKVGEKS |
| Q13247 | S297 | Sugiyama | SRSF6 SFRS6 SRP55 | RSRSPKENGKGDIKsKSRsRsQsRsNsPLPVPPsKARsVsP |
| Q14671 | S709 | Sugiyama | PUM1 KIAA0099 PUMH1 | LGGFGTAVANSNTGSGSRRDsLtGSsDLYKRTSSSLTPIGH |
| Q14896 | S275 | SIGNOR | MYBPC3 | TVHEAMGTGDLDLLSAFRRTsLAGGGRRIsDSHEDTGILDF |
| Q14896 | S284 | SIGNOR | MYBPC3 | DLDLLSAFRRTsLAGGGRRIsDSHEDTGILDFSSLLKKRDs |
| Q14896 | S304 | SIGNOR | MYBPC3 | sDSHEDTGILDFSSLLKKRDsFRTPRDsKLEAPAEEDVWEI |
| Q14896 | S311 | SIGNOR | MYBPC3 | GILDFSSLLKKRDsFRTPRDsKLEAPAEEDVWEILRQAPPS |
| Q14978 | S686 | Sugiyama | NOLC1 KIAA0035 NS5ATP13 | KGKSFRHEKTKKKRGsYRGGsIsVQVNsIKFDsE_______ |
| Q6GYQ0 | S860 | Sugiyama | RALGAPA1 GARNL1 KIAA0884 TULIP1 | DEFIAERLRSGNASTMTRRGssPGsLEIPKDLPDILNKQNQ |
| Q6PIY7 | S116 | SIGNOR | TENT2 GLD2 PAPD4 | PHQEPtVVNQIVPLsGERRYsMPPLFHTHYVPDIVRCVPPF |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q86WG5 | T1434 | Sugiyama | SBF2 CMT4B2 KIAA1766 MTMR13 | WDITAQVTSLVQLLSDPFYRtLEGFQMLVEKEWLSFGHKFS |
| Q8IZ21 | S590 | Sugiyama | PHACTR4 PRO2963 | SKEEWNEIRHQIGNTLIRRLsQRPtPEELEQRNILQPKNEA |
| Q8NFD5 | S1744 | Sugiyama | ARID1B BAF250B DAN15 KIAA1235 OSA2 | ALDTINILLYDDSTVATFNLsQLSGFLELLVEYFRKCLIDI |
| Q92766 | S1167 | Sugiyama | RREB1 FINB | AGTSKKRGRKRGMRSRPRANsGGVDLDssGEFASIEKMLAT |
| Q92934 | S118 | SIGNOR | BAD BBC6 BCL2L8 | RsAPPNLWAAQRYGRELRRMsDEFVDsFKKGLPRPKsAGtA |
| Q92934 | S75 | SIGNOR | BAD BBC6 BCL2L8 | PTSSSHHGGAGAVEIRsRHssyPAGtEDDEGMGEEPsPFRG |
| Q92934 | S99 | SIGNOR | BAD BBC6 BCL2L8 | GtEDDEGMGEEPsPFRGRsRsAPPNLWAAQRYGRELRRMsD |
| Q9BX95 | S112 | Sugiyama | SGPP1 SPP1 | GLAAELGPAsPRRAGALRRNsLtGEEGQLARVSNWPLYCLF |
| Q9BX95 | T114 | Sugiyama | SGPP1 SPP1 | AAELGPAsPRRAGALRRNsLtGEEGQLARVSNWPLYCLFCF |
| Q9C0C2 | S429 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | EEEAKGDAHLRPtsLVQRRFsEGVLQsPsQDQEKLGGsLAA |
| Q9UGV2 | S331 | Sugiyama | NDRG3 | QGMGYIPSASMTRLARsRtHstsssLGsGEsPFsRsVtsNQ |
| Q9UQ35 | S1541 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | ssVDQKtVARtPLGQRsRsGssQELDVKPsAsPQERsEsDs |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Chromatin modifying enzymes | R-HSA-3247509 | 7.493674e-08 | 7.125 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 7.335871e-08 | 7.135 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.947257e-07 | 6.711 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.830897e-07 | 6.737 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 2.406320e-07 | 6.619 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 4.814731e-07 | 6.317 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.218063e-06 | 5.654 | 1 | 0 |
| Cell Cycle | R-HSA-1640170 | 3.052141e-06 | 5.515 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 4.961619e-06 | 5.304 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 9.493840e-06 | 5.023 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 8.823021e-06 | 5.054 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 1.086558e-05 | 4.964 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 3.952153e-05 | 4.403 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 4.440439e-05 | 4.353 | 1 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 4.620477e-05 | 4.335 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.122115e-04 | 3.950 | 1 | 0 |
| Rap1 signalling | R-HSA-392517 | 1.472439e-04 | 3.832 | 1 | 1 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 2.112585e-04 | 3.675 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 2.532200e-04 | 3.597 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 3.165400e-04 | 3.500 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 3.675749e-04 | 3.435 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 3.675749e-04 | 3.435 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 3.949648e-04 | 3.403 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 4.106537e-04 | 3.387 | 1 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 7.549339e-04 | 3.122 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 1.144851e-03 | 2.941 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 1.197630e-03 | 2.922 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 1.201101e-03 | 2.920 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 1.164550e-03 | 2.934 | 1 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 1.187063e-03 | 2.926 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 1.977532e-03 | 2.704 | 1 | 1 |
| RET signaling | R-HSA-8853659 | 1.868099e-03 | 2.729 | 1 | 1 |
| Calmodulin induced events | R-HSA-111933 | 1.868099e-03 | 2.729 | 1 | 0 |
| CaM pathway | R-HSA-111997 | 1.868099e-03 | 2.729 | 1 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 1.977532e-03 | 2.704 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 1.970900e-03 | 2.705 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.943739e-03 | 2.711 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 2.063753e-03 | 2.685 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 2.354206e-03 | 2.628 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 2.403974e-03 | 2.619 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 2.452232e-03 | 2.610 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 2.761235e-03 | 2.559 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 2.892021e-03 | 2.539 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 3.024699e-03 | 2.519 | 1 | 1 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 3.263227e-03 | 2.486 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 3.533869e-03 | 2.452 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 3.851104e-03 | 2.414 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 4.076202e-03 | 2.390 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 4.279152e-03 | 2.369 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 4.506281e-03 | 2.346 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 4.729225e-03 | 2.325 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 4.935404e-03 | 2.307 | 1 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 5.535850e-03 | 2.257 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 5.535850e-03 | 2.257 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 5.508753e-03 | 2.259 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 5.587835e-03 | 2.253 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 5.978291e-03 | 2.223 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 6.366910e-03 | 2.196 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 6.453463e-03 | 2.190 | 1 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 6.601559e-03 | 2.180 | 0 | 0 |
| Kinesins | R-HSA-983189 | 6.846161e-03 | 2.165 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 7.308857e-03 | 2.136 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 7.259191e-03 | 2.139 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 7.614533e-03 | 2.118 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 7.837372e-03 | 2.106 | 1 | 1 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 8.435326e-03 | 2.074 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 8.473062e-03 | 2.072 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 8.670206e-03 | 2.062 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 8.844232e-03 | 2.053 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 9.375632e-03 | 2.028 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 9.375632e-03 | 2.028 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 9.440049e-03 | 2.025 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 9.688294e-03 | 2.014 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 1.161206e-02 | 1.935 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 1.161206e-02 | 1.935 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 1.161206e-02 | 1.935 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 1.161206e-02 | 1.935 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 1.161206e-02 | 1.935 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 1.165167e-02 | 1.934 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 1.165167e-02 | 1.934 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 1.165167e-02 | 1.934 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.021369e-02 | 1.991 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 1.160216e-02 | 1.935 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 1.160216e-02 | 1.935 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 1.082723e-02 | 1.965 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 1.165167e-02 | 1.934 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 1.012188e-02 | 1.995 | 1 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 1.097152e-02 | 1.960 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 1.050931e-02 | 1.978 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 1.165269e-02 | 1.934 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 1.165269e-02 | 1.934 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 1.183336e-02 | 1.927 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 1.274159e-02 | 1.895 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 1.295049e-02 | 1.888 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 1.327043e-02 | 1.877 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 1.455324e-02 | 1.837 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 1.421788e-02 | 1.847 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 1.391634e-02 | 1.856 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 1.364477e-02 | 1.865 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 1.462754e-02 | 1.835 | 1 | 1 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 1.462754e-02 | 1.835 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 1.611420e-02 | 1.793 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 1.506431e-02 | 1.822 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 1.526127e-02 | 1.816 | 0 | 0 |
| M Phase | R-HSA-68886 | 1.605200e-02 | 1.794 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 1.519518e-02 | 1.818 | 1 | 1 |
| MTOR signalling | R-HSA-165159 | 1.527997e-02 | 1.816 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 1.524236e-02 | 1.817 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 1.647031e-02 | 1.783 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 1.647031e-02 | 1.783 | 1 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.672311e-02 | 1.777 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 1.692174e-02 | 1.772 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 1.702035e-02 | 1.769 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 1.702035e-02 | 1.769 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 1.744241e-02 | 1.758 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 1.844083e-02 | 1.734 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.722958e-02 | 1.764 | 1 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.856495e-02 | 1.731 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 1.947996e-02 | 1.710 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 2.287755e-02 | 1.641 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 2.287755e-02 | 1.641 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 2.287755e-02 | 1.641 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 2.287755e-02 | 1.641 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 2.287755e-02 | 1.641 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.256155e-02 | 1.647 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 2.398642e-02 | 1.620 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 2.452891e-02 | 1.610 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 2.452891e-02 | 1.610 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 2.452891e-02 | 1.610 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 2.452891e-02 | 1.610 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 2.623027e-02 | 1.581 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 2.537870e-02 | 1.596 | 1 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 2.452085e-02 | 1.610 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 2.522872e-02 | 1.598 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 2.522872e-02 | 1.598 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 2.625420e-02 | 1.581 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 2.522872e-02 | 1.598 | 1 | 1 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 2.421413e-02 | 1.616 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 2.623027e-02 | 1.581 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 2.649268e-02 | 1.577 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 2.668602e-02 | 1.574 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 2.681602e-02 | 1.572 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 2.787104e-02 | 1.555 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 2.798166e-02 | 1.553 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 2.934440e-02 | 1.532 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 2.901850e-02 | 1.537 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 2.975939e-02 | 1.526 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 3.109113e-02 | 1.507 | 1 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 3.036523e-02 | 1.518 | 1 | 1 |
| Opioid Signalling | R-HSA-111885 | 2.977015e-02 | 1.526 | 1 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 2.980280e-02 | 1.526 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 2.915040e-02 | 1.535 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 3.160108e-02 | 1.500 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 3.160108e-02 | 1.500 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 3.036523e-02 | 1.518 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 3.277532e-02 | 1.484 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 3.310181e-02 | 1.480 | 0 | 0 |
| Transcriptional activation of cell cycle inhibitor p21 | R-HSA-69895 | 3.322615e-02 | 1.479 | 0 | 0 |
| Transcriptional activation of p53 responsive genes | R-HSA-69560 | 3.322615e-02 | 1.479 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 3.346461e-02 | 1.475 | 1 | 1 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 3.439183e-02 | 1.464 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.459879e-02 | 1.461 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 3.481996e-02 | 1.458 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 3.506438e-02 | 1.455 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 3.530802e-02 | 1.452 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 3.695729e-02 | 1.432 | 1 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 3.695301e-02 | 1.432 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 3.961913e-02 | 1.402 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 3.982927e-02 | 1.400 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 4.001266e-02 | 1.398 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 4.001266e-02 | 1.398 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 4.001266e-02 | 1.398 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 4.009300e-02 | 1.397 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 4.016861e-02 | 1.396 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 4.043265e-02 | 1.393 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 4.247507e-02 | 1.372 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 4.248202e-02 | 1.372 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 4.271138e-02 | 1.369 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 4.322944e-02 | 1.364 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 4.329607e-02 | 1.364 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 4.775481e-02 | 1.321 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 4.855810e-02 | 1.314 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 4.855810e-02 | 1.314 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 4.575323e-02 | 1.340 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 4.683545e-02 | 1.329 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 4.507249e-02 | 1.346 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 4.924427e-02 | 1.308 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 4.924427e-02 | 1.308 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 4.461423e-02 | 1.351 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 4.855810e-02 | 1.314 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 4.916740e-02 | 1.308 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 4.940751e-02 | 1.306 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 5.183217e-02 | 1.285 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 5.196977e-02 | 1.284 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 5.201817e-02 | 1.284 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 5.201817e-02 | 1.284 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 5.271010e-02 | 1.278 | 0 | 0 |
| PKA activation | R-HSA-163615 | 5.307215e-02 | 1.275 | 1 | 1 |
| PKA activation in glucagon signalling | R-HSA-164378 | 5.307215e-02 | 1.275 | 1 | 1 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 5.307215e-02 | 1.275 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 5.307215e-02 | 1.275 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 5.307215e-02 | 1.275 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 5.403151e-02 | 1.267 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 5.492724e-02 | 1.260 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 5.986003e-02 | 1.223 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 6.075733e-02 | 1.216 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 6.075733e-02 | 1.216 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 5.572484e-02 | 1.254 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 6.202670e-02 | 1.207 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 6.294099e-02 | 1.201 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 5.749653e-02 | 1.240 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 5.764839e-02 | 1.239 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 5.646571e-02 | 1.248 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 6.294099e-02 | 1.201 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 5.812131e-02 | 1.236 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 6.164137e-02 | 1.210 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 6.366611e-02 | 1.196 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 6.464586e-02 | 1.189 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 6.472669e-02 | 1.189 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 6.566386e-02 | 1.183 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 6.566386e-02 | 1.183 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 6.566386e-02 | 1.183 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 6.674563e-02 | 1.176 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 6.674563e-02 | 1.176 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 6.674563e-02 | 1.176 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 6.992441e-02 | 1.155 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 7.098022e-02 | 1.149 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 7.134241e-02 | 1.147 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 7.134241e-02 | 1.147 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 7.134241e-02 | 1.147 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 7.134241e-02 | 1.147 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 7.167425e-02 | 1.145 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 7.167425e-02 | 1.145 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 7.167425e-02 | 1.145 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 7.167425e-02 | 1.145 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 7.198697e-02 | 1.143 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 7.882307e-02 | 1.103 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 7.882307e-02 | 1.103 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 8.466931e-02 | 1.072 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 7.272096e-02 | 1.138 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 7.779008e-02 | 1.109 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 7.608716e-02 | 1.119 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 8.098083e-02 | 1.092 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 8.244839e-02 | 1.084 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 8.173069e-02 | 1.088 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 8.466931e-02 | 1.072 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 8.109940e-02 | 1.091 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 8.244839e-02 | 1.084 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 7.732504e-02 | 1.112 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 8.063813e-02 | 1.093 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 8.652863e-02 | 1.063 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 8.652863e-02 | 1.063 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 8.887487e-02 | 1.051 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 9.198018e-02 | 1.036 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 1.090330e-01 | 0.962 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 1.090330e-01 | 0.962 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 1.090330e-01 | 0.962 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 1.090330e-01 | 0.962 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 1.090330e-01 | 0.962 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 1.090330e-01 | 0.962 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 1.090330e-01 | 0.962 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 1.090330e-01 | 0.962 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 1.090330e-01 | 0.962 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 1.090330e-01 | 0.962 | 0 | 0 |
| Defective translocation of RB1 mutants to the nucleus | R-HSA-9661070 | 1.090330e-01 | 0.962 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 1.090330e-01 | 0.962 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 1.090330e-01 | 0.962 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 1.090330e-01 | 0.962 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 1.090330e-01 | 0.962 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 1.090330e-01 | 0.962 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 1.090330e-01 | 0.962 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 1.107315e-01 | 0.956 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 1.107315e-01 | 0.956 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 1.107315e-01 | 0.956 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 1.107315e-01 | 0.956 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 1.107315e-01 | 0.956 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 1.107315e-01 | 0.956 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 9.789254e-02 | 1.009 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 9.789254e-02 | 1.009 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 9.599848e-02 | 1.018 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 9.634301e-02 | 1.016 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 9.915066e-02 | 1.004 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.006155e-01 | 0.997 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 9.300235e-02 | 1.032 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 1.011307e-01 | 0.995 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 1.009617e-01 | 0.996 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.073131e-01 | 0.969 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 9.599848e-02 | 1.018 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 1.047490e-01 | 0.980 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 1.067618e-01 | 0.972 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 9.983937e-02 | 1.001 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 9.246321e-02 | 1.034 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 1.078770e-01 | 0.967 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 9.789254e-02 | 1.009 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 9.599848e-02 | 1.018 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 1.089608e-01 | 0.963 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 1.025593e-01 | 0.989 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 1.025593e-01 | 0.989 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 1.112612e-01 | 0.954 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 1.139441e-01 | 0.943 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 1.140625e-01 | 0.943 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 1.144380e-01 | 0.941 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 1.144380e-01 | 0.941 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 2.061835e-01 | 0.686 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 2.061835e-01 | 0.686 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 2.061835e-01 | 0.686 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 2.061835e-01 | 0.686 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 1.532398e-01 | 0.815 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 1.532398e-01 | 0.815 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 1.532398e-01 | 0.815 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 1.532398e-01 | 0.815 | 0 | 0 |
| PI and PC transport between ER and Golgi membranes | R-HSA-1483196 | 2.927459e-01 | 0.534 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 2.927459e-01 | 0.534 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 2.927459e-01 | 0.534 | 0 | 0 |
| TGFBR3 regulates FGF2 signaling | R-HSA-9839397 | 2.927459e-01 | 0.534 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 2.927459e-01 | 0.534 | 0 | 0 |
| MyD88 deficiency (TLR5) | R-HSA-5602680 | 2.927459e-01 | 0.534 | 0 | 0 |
| Intestinal infectious diseases | R-HSA-8942233 | 2.927459e-01 | 0.534 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5660686 | 2.927459e-01 | 0.534 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 2.927459e-01 | 0.534 | 0 | 0 |
| Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG) | R-HSA-5619101 | 2.927459e-01 | 0.534 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 2.927459e-01 | 0.534 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 2.927459e-01 | 0.534 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.927459e-01 | 0.534 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 2.927459e-01 | 0.534 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 2.927459e-01 | 0.534 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 2.927459e-01 | 0.534 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.927459e-01 | 0.534 | 0 | 0 |
| Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome | R-HSA-5678420 | 2.927459e-01 | 0.534 | 0 | 0 |
| PTEN Loss of Function in Cancer | R-HSA-5674404 | 2.927459e-01 | 0.534 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 1.941111e-01 | 0.712 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 1.941111e-01 | 0.712 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.941111e-01 | 0.712 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 1.359536e-01 | 0.867 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 1.359536e-01 | 0.867 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 2.361399e-01 | 0.627 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 2.361399e-01 | 0.627 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 2.361399e-01 | 0.627 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 3.698735e-01 | 0.432 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 3.698735e-01 | 0.432 | 0 | 0 |
| Interaction between PHLDA1 and AURKA | R-HSA-8854521 | 3.698735e-01 | 0.432 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 3.698735e-01 | 0.432 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 3.698735e-01 | 0.432 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.698735e-01 | 0.432 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 3.698735e-01 | 0.432 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 3.698735e-01 | 0.432 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 3.698735e-01 | 0.432 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 3.698735e-01 | 0.432 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 3.698735e-01 | 0.432 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 3.698735e-01 | 0.432 | 0 | 0 |
| TWIK related potassium channel (TREK) | R-HSA-1299503 | 3.698735e-01 | 0.432 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 3.698735e-01 | 0.432 | 0 | 0 |
| Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum) | R-HSA-5655799 | 3.698735e-01 | 0.432 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 3.698735e-01 | 0.432 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 3.698735e-01 | 0.432 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 3.698735e-01 | 0.432 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 3.698735e-01 | 0.432 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 1.360865e-01 | 0.866 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 1.360865e-01 | 0.866 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 1.360865e-01 | 0.866 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 1.912974e-01 | 0.718 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 1.912974e-01 | 0.718 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 1.912974e-01 | 0.718 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 1.912974e-01 | 0.718 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 2.785885e-01 | 0.555 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 2.785885e-01 | 0.555 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 2.785885e-01 | 0.555 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 2.785885e-01 | 0.555 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 2.785885e-01 | 0.555 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 1.303607e-01 | 0.885 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 1.792662e-01 | 0.747 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 1.792662e-01 | 0.747 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 1.476431e-01 | 0.831 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 1.476431e-01 | 0.831 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 1.658366e-01 | 0.780 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 1.658366e-01 | 0.780 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 1.658366e-01 | 0.780 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 1.658366e-01 | 0.780 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 1.658366e-01 | 0.780 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 1.658366e-01 | 0.780 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 2.023745e-01 | 0.694 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 2.511248e-01 | 0.600 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 2.511248e-01 | 0.600 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 3.208659e-01 | 0.494 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 3.208659e-01 | 0.494 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 3.208659e-01 | 0.494 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 3.208659e-01 | 0.494 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 3.208659e-01 | 0.494 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 4.385942e-01 | 0.358 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 4.385942e-01 | 0.358 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 4.385942e-01 | 0.358 | 0 | 0 |
| IRAK4 deficiency (TLR5) | R-HSA-5603037 | 4.385942e-01 | 0.358 | 0 | 0 |
| Defective ABCA1 causes TGD | R-HSA-5682113 | 4.385942e-01 | 0.358 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 4.385942e-01 | 0.358 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 1.273215e-01 | 0.895 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 1.527841e-01 | 0.816 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 1.527841e-01 | 0.816 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 1.848620e-01 | 0.733 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 2.262988e-01 | 0.645 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 2.262988e-01 | 0.645 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 1.405927e-01 | 0.852 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 1.689013e-01 | 0.772 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 2.820038e-01 | 0.550 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.293694e-01 | 0.888 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 1.856922e-01 | 0.731 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 1.856922e-01 | 0.731 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 1.856922e-01 | 0.731 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 2.508913e-01 | 0.601 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 3.625050e-01 | 0.441 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 3.625050e-01 | 0.441 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 3.625050e-01 | 0.441 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.690149e-01 | 0.772 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 2.250681e-01 | 0.648 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 2.031024e-01 | 0.692 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 2.031024e-01 | 0.692 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.031024e-01 | 0.692 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.031024e-01 | 0.692 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 3.131838e-01 | 0.504 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 3.131838e-01 | 0.504 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 1.186018e-01 | 0.926 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 1.674575e-01 | 0.776 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 1.674575e-01 | 0.776 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 2.210743e-01 | 0.655 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 2.210743e-01 | 0.655 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 1.997166e-01 | 0.700 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 1.997166e-01 | 0.700 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 1.811805e-01 | 0.742 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 1.811805e-01 | 0.742 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 1.811805e-01 | 0.742 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 1.811805e-01 | 0.742 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 1.649093e-01 | 0.783 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 1.649093e-01 | 0.783 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 1.505029e-01 | 0.822 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 1.157921e-01 | 0.936 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 3.015049e-01 | 0.521 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 3.015049e-01 | 0.521 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 3.444366e-01 | 0.463 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 3.444366e-01 | 0.463 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 4.031426e-01 | 0.395 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 4.031426e-01 | 0.395 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 4.998239e-01 | 0.301 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 4.998239e-01 | 0.301 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 4.998239e-01 | 0.301 | 0 | 0 |
| ATP sensitive Potassium channels | R-HSA-1296025 | 4.998239e-01 | 0.301 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 4.998239e-01 | 0.301 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 4.998239e-01 | 0.301 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 1.582509e-01 | 0.801 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 1.582509e-01 | 0.801 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 2.323858e-01 | 0.634 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 2.894300e-01 | 0.538 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 3.755579e-01 | 0.425 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 3.755579e-01 | 0.425 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 3.755579e-01 | 0.425 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 3.755579e-01 | 0.425 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 1.601043e-01 | 0.796 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 4.425020e-01 | 0.354 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 4.425020e-01 | 0.354 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 4.425020e-01 | 0.354 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 3.339969e-01 | 0.476 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 3.339969e-01 | 0.476 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 1.538337e-01 | 0.813 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 4.063672e-01 | 0.391 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 4.063672e-01 | 0.391 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 4.063672e-01 | 0.391 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 1.755150e-01 | 0.756 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 3.022292e-01 | 0.520 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 3.789827e-01 | 0.421 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 3.565194e-01 | 0.448 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 3.372822e-01 | 0.472 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 4.047394e-01 | 0.393 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 4.367071e-01 | 0.360 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 4.367071e-01 | 0.360 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 4.367071e-01 | 0.360 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 4.367071e-01 | 0.360 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 4.803789e-01 | 0.318 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 5.543788e-01 | 0.256 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 5.543788e-01 | 0.256 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 5.543788e-01 | 0.256 | 0 | 0 |
| Defective SLC1A3 causes episodic ataxia 6 (EA6) | R-HSA-5619062 | 5.543788e-01 | 0.256 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 5.543788e-01 | 0.256 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 5.543788e-01 | 0.256 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 5.543788e-01 | 0.256 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 4.016431e-01 | 0.396 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 4.016431e-01 | 0.396 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 4.302851e-01 | 0.366 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 4.240968e-01 | 0.373 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 4.240968e-01 | 0.373 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 3.903391e-01 | 0.409 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 3.903391e-01 | 0.409 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 4.555278e-01 | 0.341 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 4.555278e-01 | 0.341 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 5.166285e-01 | 0.287 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 5.166285e-01 | 0.287 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 5.166285e-01 | 0.287 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 5.166285e-01 | 0.287 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 3.291462e-01 | 0.483 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 3.865100e-01 | 0.413 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 3.827425e-01 | 0.417 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 4.463877e-01 | 0.350 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 4.954590e-01 | 0.305 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 4.954590e-01 | 0.305 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 4.954590e-01 | 0.305 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 4.312888e-01 | 0.365 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 4.684539e-01 | 0.329 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 4.349265e-01 | 0.362 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 4.224364e-01 | 0.374 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 4.782892e-01 | 0.320 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 5.236623e-01 | 0.281 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 5.511553e-01 | 0.259 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 5.511553e-01 | 0.259 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 5.511553e-01 | 0.259 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 5.511553e-01 | 0.259 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 5.511553e-01 | 0.259 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 4.979126e-01 | 0.303 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 4.979126e-01 | 0.303 | 1 | 1 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 5.286596e-01 | 0.277 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 5.286596e-01 | 0.277 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 5.172753e-01 | 0.286 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 5.327627e-01 | 0.273 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 5.519576e-01 | 0.258 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 5.519576e-01 | 0.258 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 5.568364e-01 | 0.254 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 5.746308e-01 | 0.241 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 5.746308e-01 | 0.241 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 2.323858e-01 | 0.634 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.690149e-01 | 0.772 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 4.684539e-01 | 0.329 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 2.945804e-01 | 0.531 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 1.405927e-01 | 0.852 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 1.658366e-01 | 0.780 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 4.016431e-01 | 0.396 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 3.927621e-01 | 0.406 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 2.493515e-01 | 0.603 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 4.240968e-01 | 0.373 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 4.331052e-01 | 0.363 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 2.106114e-01 | 0.677 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 5.509757e-01 | 0.259 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 1.303607e-01 | 0.885 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 1.815116e-01 | 0.741 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 1.983664e-01 | 0.703 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 1.983664e-01 | 0.703 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 1.163000e-01 | 0.934 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 2.262988e-01 | 0.645 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 1.165981e-01 | 0.933 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 2.722925e-01 | 0.565 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 5.511553e-01 | 0.259 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 2.562255e-01 | 0.591 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 4.156967e-01 | 0.381 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 4.979126e-01 | 0.303 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 1.983664e-01 | 0.703 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 4.436717e-01 | 0.353 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 4.367071e-01 | 0.360 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 4.584440e-01 | 0.339 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 5.452822e-01 | 0.263 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 5.409783e-01 | 0.267 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 2.158262e-01 | 0.666 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 1.326038e-01 | 0.877 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 4.281983e-01 | 0.368 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 5.509757e-01 | 0.259 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 5.452822e-01 | 0.263 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 3.865100e-01 | 0.413 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 1.792662e-01 | 0.747 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 2.106114e-01 | 0.677 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 4.436717e-01 | 0.353 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.629137e-01 | 0.788 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 1.912974e-01 | 0.718 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 1.953731e-01 | 0.709 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 3.927621e-01 | 0.406 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 2.942768e-01 | 0.531 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 1.602068e-01 | 0.795 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 4.954590e-01 | 0.305 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 5.326263e-01 | 0.274 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 3.208659e-01 | 0.494 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 1.545011e-01 | 0.811 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 1.542318e-01 | 0.812 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 1.506955e-01 | 0.822 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 4.047394e-01 | 0.393 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 4.192068e-01 | 0.378 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 3.675684e-01 | 0.435 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 1.997166e-01 | 0.700 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 4.954590e-01 | 0.305 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 4.079553e-01 | 0.389 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 4.115034e-01 | 0.386 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 1.629137e-01 | 0.788 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 4.463877e-01 | 0.350 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 3.172269e-01 | 0.499 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 2.511248e-01 | 0.600 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 2.820038e-01 | 0.550 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 3.625050e-01 | 0.441 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 3.625050e-01 | 0.441 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 3.444366e-01 | 0.463 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 4.031426e-01 | 0.395 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 4.031426e-01 | 0.395 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.998239e-01 | 0.301 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 1.268332e-01 | 0.897 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 2.973642e-01 | 0.527 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 2.232643e-01 | 0.651 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 2.195556e-01 | 0.658 | 1 | 1 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.026487e-01 | 0.395 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 1.315462e-01 | 0.881 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 1.315462e-01 | 0.881 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 2.973642e-01 | 0.527 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 4.367071e-01 | 0.360 | 0 | 0 |
| S Phase | R-HSA-69242 | 2.170578e-01 | 0.663 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 1.912974e-01 | 0.718 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 1.912974e-01 | 0.718 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 2.820038e-01 | 0.550 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.190948e-01 | 0.924 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 5.511553e-01 | 0.259 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 5.511553e-01 | 0.259 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 5.586269e-01 | 0.253 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 3.790520e-01 | 0.421 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 3.434512e-01 | 0.464 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 4.590766e-01 | 0.338 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 1.811805e-01 | 0.742 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.179699e-01 | 0.928 | 1 | 1 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 1.340651e-01 | 0.873 | 1 | 0 |
| Signaling by WNT | R-HSA-195721 | 2.094537e-01 | 0.679 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 1.629137e-01 | 0.788 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 1.571217e-01 | 0.804 | 1 | 1 |
| Abacavir transmembrane transport | R-HSA-2161517 | 2.785885e-01 | 0.555 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 1.373917e-01 | 0.862 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 3.625050e-01 | 0.441 | 0 | 0 |
| Astrocytic Glutamate-Glutamine Uptake And Metabolism | R-HSA-210455 | 3.625050e-01 | 0.441 | 0 | 0 |
| Neurotransmitter uptake and metabolism In glial cells | R-HSA-112313 | 3.625050e-01 | 0.441 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 3.015049e-01 | 0.521 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 3.172269e-01 | 0.499 | 1 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 4.803789e-01 | 0.318 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 3.389133e-01 | 0.470 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 3.756306e-01 | 0.425 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 4.182597e-01 | 0.379 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 5.166285e-01 | 0.287 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 4.127629e-01 | 0.384 | 1 | 1 |
| Nuclear RNA decay | R-HSA-9930044 | 4.684539e-01 | 0.329 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 4.684539e-01 | 0.329 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 4.760791e-01 | 0.322 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 4.375834e-01 | 0.359 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 5.172753e-01 | 0.286 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 4.943753e-01 | 0.306 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 5.773389e-01 | 0.239 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 2.713624e-01 | 0.566 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 2.611394e-01 | 0.583 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 3.777329e-01 | 0.423 | 1 | 1 |
| IGF1R signaling cascade | R-HSA-2428924 | 4.510129e-01 | 0.346 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 5.550794e-01 | 0.256 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 5.550794e-01 | 0.256 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 4.543879e-01 | 0.343 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.034988e-01 | 0.518 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 4.902388e-01 | 0.310 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 1.346756e-01 | 0.871 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 3.386469e-01 | 0.470 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 3.503615e-01 | 0.455 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.604745e-01 | 0.795 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 3.386469e-01 | 0.470 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 5.172753e-01 | 0.286 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 1.983664e-01 | 0.703 | 1 | 0 |
| Signalling to ERKs | R-HSA-187687 | 1.177751e-01 | 0.929 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 3.189556e-01 | 0.496 | 1 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 3.865100e-01 | 0.413 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 3.865100e-01 | 0.413 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 3.865100e-01 | 0.413 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 3.865100e-01 | 0.413 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 3.684867e-01 | 0.434 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 1.918217e-01 | 0.717 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 1.532398e-01 | 0.815 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 2.785885e-01 | 0.555 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 1.690149e-01 | 0.772 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 3.444366e-01 | 0.463 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 4.031426e-01 | 0.395 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 4.425020e-01 | 0.354 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 5.543788e-01 | 0.256 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 4.664424e-01 | 0.331 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 4.680664e-01 | 0.330 | 1 | 1 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 4.588492e-01 | 0.338 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 5.220253e-01 | 0.282 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 3.941966e-01 | 0.404 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 2.705672e-01 | 0.568 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 1.279361e-01 | 0.893 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 5.509757e-01 | 0.259 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.232643e-01 | 0.651 | 1 | 1 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 4.670304e-01 | 0.331 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 2.012916e-01 | 0.696 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 5.326263e-01 | 0.274 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 4.277738e-01 | 0.369 | 1 | 0 |
| Macroautophagy | R-HSA-1632852 | 1.576159e-01 | 0.802 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 2.262988e-01 | 0.645 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 5.326839e-01 | 0.274 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 5.746308e-01 | 0.241 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 2.788492e-01 | 0.555 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 1.390061e-01 | 0.857 | 1 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 4.906773e-01 | 0.309 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 3.208659e-01 | 0.494 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.423505e-01 | 0.847 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 3.756107e-01 | 0.425 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 3.756107e-01 | 0.425 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 2.533506e-01 | 0.596 | 1 | 0 |
| Potassium Channels | R-HSA-1296071 | 4.644194e-01 | 0.333 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 4.906773e-01 | 0.309 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 4.906773e-01 | 0.309 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 1.208167e-01 | 0.918 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 1.204474e-01 | 0.919 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 4.349265e-01 | 0.362 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 5.601109e-01 | 0.252 | 1 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 2.417901e-01 | 0.617 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 4.555278e-01 | 0.341 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 4.564408e-01 | 0.341 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.376613e-01 | 0.861 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 5.236623e-01 | 0.281 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 1.158793e-01 | 0.936 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 1.842294e-01 | 0.735 | 1 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 1.483209e-01 | 0.829 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.777554e-01 | 0.556 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 4.132066e-01 | 0.384 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 4.089753e-01 | 0.388 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 4.520509e-01 | 0.345 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 2.061835e-01 | 0.686 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 1.629137e-01 | 0.788 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 1.629137e-01 | 0.788 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 2.361399e-01 | 0.627 | 0 | 0 |
| Defective ABCC8 can cause hypo- and hyper-glycemias | R-HSA-5683177 | 3.698735e-01 | 0.432 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 3.698735e-01 | 0.432 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.303607e-01 | 0.885 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 2.023745e-01 | 0.694 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 4.385942e-01 | 0.358 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 2.820038e-01 | 0.550 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 1.811805e-01 | 0.742 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 4.998239e-01 | 0.301 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 4.998239e-01 | 0.301 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 2.250476e-01 | 0.648 | 1 | 1 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 4.425020e-01 | 0.354 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 3.790935e-01 | 0.421 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 4.367071e-01 | 0.360 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 4.803789e-01 | 0.318 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 5.543788e-01 | 0.256 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 5.543788e-01 | 0.256 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 3.187791e-01 | 0.497 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 5.166285e-01 | 0.287 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 4.954590e-01 | 0.305 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 4.444391e-01 | 0.352 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 5.286596e-01 | 0.277 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 5.042430e-01 | 0.297 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 5.519576e-01 | 0.258 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 5.202696e-01 | 0.284 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 5.773389e-01 | 0.239 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 5.736074e-01 | 0.241 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 5.744810e-01 | 0.241 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 4.658982e-01 | 0.332 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 4.965009e-01 | 0.304 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 1.882795e-01 | 0.725 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 5.039117e-01 | 0.298 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 1.326038e-01 | 0.877 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 3.772730e-01 | 0.423 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 5.327627e-01 | 0.273 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 5.428982e-01 | 0.265 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 5.047836e-01 | 0.297 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 2.722925e-01 | 0.565 | 1 | 1 |
| FLT3 signaling in disease | R-HSA-9682385 | 2.323858e-01 | 0.634 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 1.490965e-01 | 0.827 | 1 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 5.449542e-01 | 0.264 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 2.605108e-01 | 0.584 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.190447e-01 | 0.659 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 3.005206e-01 | 0.522 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 2.826440e-01 | 0.549 | 1 | 1 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 1.690149e-01 | 0.772 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 5.568364e-01 | 0.254 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 3.625050e-01 | 0.441 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.250681e-01 | 0.648 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 4.367071e-01 | 0.360 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 2.948336e-01 | 0.530 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 5.519576e-01 | 0.258 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 5.746308e-01 | 0.241 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 5.736074e-01 | 0.241 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 4.954590e-01 | 0.305 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 5.519576e-01 | 0.258 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 2.023676e-01 | 0.694 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 1.629137e-01 | 0.788 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 1.629137e-01 | 0.788 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 2.361399e-01 | 0.627 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 3.131838e-01 | 0.504 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 1.173946e-01 | 0.930 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 4.031426e-01 | 0.395 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 4.031426e-01 | 0.395 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 3.272505e-01 | 0.485 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 3.474076e-01 | 0.459 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 4.902388e-01 | 0.310 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 5.511553e-01 | 0.259 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 5.511553e-01 | 0.259 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 5.511553e-01 | 0.259 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 5.753459e-01 | 0.240 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 4.349265e-01 | 0.362 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 4.349265e-01 | 0.362 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 5.061203e-01 | 0.296 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 5.116905e-01 | 0.291 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 2.511903e-01 | 0.600 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 4.031426e-01 | 0.395 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 2.894300e-01 | 0.538 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 5.047836e-01 | 0.297 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 4.889889e-01 | 0.311 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 2.973642e-01 | 0.527 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 1.216909e-01 | 0.915 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 1.303607e-01 | 0.885 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 4.026487e-01 | 0.395 | 1 | 0 |
| PI Metabolism | R-HSA-1483255 | 2.397924e-01 | 0.620 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 2.763852e-01 | 0.558 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 2.370747e-01 | 0.625 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 4.664424e-01 | 0.331 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 2.195556e-01 | 0.658 | 1 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 2.039560e-01 | 0.690 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 5.534139e-01 | 0.257 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 3.339969e-01 | 0.476 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 1.240355e-01 | 0.906 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 3.675684e-01 | 0.435 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 2.927459e-01 | 0.534 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 2.361399e-01 | 0.627 | 0 | 0 |
| DSCAM interactions | R-HSA-376172 | 3.698735e-01 | 0.432 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 1.912974e-01 | 0.718 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 2.207984e-01 | 0.656 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 3.625050e-01 | 0.441 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 3.444366e-01 | 0.463 | 0 | 0 |
| Sensory perception of sour taste | R-HSA-9729555 | 4.998239e-01 | 0.301 | 0 | 0 |
| LTC4-CYSLTR mediated IL4 production | R-HSA-9664535 | 4.425020e-01 | 0.354 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 4.063672e-01 | 0.391 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 5.543788e-01 | 0.256 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 3.865100e-01 | 0.413 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 4.384191e-01 | 0.358 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 5.773389e-01 | 0.239 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 5.746308e-01 | 0.241 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 2.039560e-01 | 0.690 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 4.555278e-01 | 0.341 | 1 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 4.139620e-01 | 0.383 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 4.782892e-01 | 0.320 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 5.478723e-01 | 0.261 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 2.785885e-01 | 0.555 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 4.385942e-01 | 0.358 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 1.587405e-01 | 0.799 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 5.116905e-01 | 0.291 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 5.144350e-01 | 0.289 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 5.236623e-01 | 0.281 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 2.323858e-01 | 0.634 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 3.755579e-01 | 0.425 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 4.312888e-01 | 0.365 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 4.384191e-01 | 0.358 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 4.312888e-01 | 0.365 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 3.719237e-01 | 0.430 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 4.684539e-01 | 0.329 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 1.941111e-01 | 0.712 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 2.361399e-01 | 0.627 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 3.208659e-01 | 0.494 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 3.208659e-01 | 0.494 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 4.385942e-01 | 0.358 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 3.625050e-01 | 0.441 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 4.031426e-01 | 0.395 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 4.998239e-01 | 0.301 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.998239e-01 | 0.301 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 5.543788e-01 | 0.256 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 3.777329e-01 | 0.423 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 3.474076e-01 | 0.459 | 1 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 4.684539e-01 | 0.329 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 3.894666e-01 | 0.410 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 4.590766e-01 | 0.338 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 5.511553e-01 | 0.259 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 2.894300e-01 | 0.538 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 5.509757e-01 | 0.259 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 2.843194e-01 | 0.546 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 5.511553e-01 | 0.259 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 5.773389e-01 | 0.239 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 5.736074e-01 | 0.241 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 4.031426e-01 | 0.395 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 4.803789e-01 | 0.318 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 5.543788e-01 | 0.256 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 4.463877e-01 | 0.350 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 2.545239e-01 | 0.594 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 2.760070e-01 | 0.559 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 3.531162e-01 | 0.452 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 5.511553e-01 | 0.259 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 4.330062e-01 | 0.364 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 5.172753e-01 | 0.286 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 5.172753e-01 | 0.286 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 3.789827e-01 | 0.421 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 3.372822e-01 | 0.472 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 5.543788e-01 | 0.256 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 5.511553e-01 | 0.259 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 2.760070e-01 | 0.559 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 4.425020e-01 | 0.354 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 5.785730e-01 | 0.238 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 5.809706e-01 | 0.236 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 5.820100e-01 | 0.235 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 5.839038e-01 | 0.234 | 0 | 0 |
| PI5P Regulates TP53 Acetylation | R-HSA-6811555 | 5.839038e-01 | 0.234 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 5.839038e-01 | 0.234 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 5.839038e-01 | 0.234 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 5.900423e-01 | 0.229 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 5.900700e-01 | 0.229 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 5.900700e-01 | 0.229 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 5.903138e-01 | 0.229 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 5.912926e-01 | 0.228 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 5.914554e-01 | 0.228 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 5.932759e-01 | 0.227 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 5.933117e-01 | 0.227 | 0 | 0 |
| Depurination | R-HSA-73927 | 5.933117e-01 | 0.227 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 5.933117e-01 | 0.227 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 5.966401e-01 | 0.224 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 5.966401e-01 | 0.224 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 5.966401e-01 | 0.224 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 5.966401e-01 | 0.224 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 6.027066e-01 | 0.220 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 6.027066e-01 | 0.220 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 6.027066e-01 | 0.220 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 6.029861e-01 | 0.220 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 6.029861e-01 | 0.220 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 6.029861e-01 | 0.220 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 6.029861e-01 | 0.220 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 6.029861e-01 | 0.220 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 6.029861e-01 | 0.220 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 6.029861e-01 | 0.220 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 6.029861e-01 | 0.220 | 0 | 0 |
| Defective CSF2RB causes SMDP5 | R-HSA-5688849 | 6.029861e-01 | 0.220 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 6.029861e-01 | 0.220 | 0 | 0 |
| Defective CSF2RA causes SMDP4 | R-HSA-5688890 | 6.029861e-01 | 0.220 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 6.029861e-01 | 0.220 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 6.029861e-01 | 0.220 | 0 | 0 |
| NGF-independant TRKA activation | R-HSA-187024 | 6.029861e-01 | 0.220 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 6.029861e-01 | 0.220 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 6.029861e-01 | 0.220 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 6.029861e-01 | 0.220 | 0 | 0 |
| Formation of the Editosome | R-HSA-75094 | 6.029861e-01 | 0.220 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 6.029861e-01 | 0.220 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 6.029861e-01 | 0.220 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 6.029861e-01 | 0.220 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 6.029861e-01 | 0.220 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 6.029861e-01 | 0.220 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 6.029861e-01 | 0.220 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 6.029861e-01 | 0.220 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 6.050039e-01 | 0.218 | 1 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 6.053773e-01 | 0.218 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 6.068110e-01 | 0.217 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 6.148512e-01 | 0.211 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 6.148512e-01 | 0.211 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 6.148512e-01 | 0.211 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 6.148512e-01 | 0.211 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 6.148512e-01 | 0.211 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 6.163333e-01 | 0.210 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 6.171030e-01 | 0.210 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 6.184751e-01 | 0.209 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 6.186919e-01 | 0.209 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 6.228790e-01 | 0.206 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 6.270467e-01 | 0.203 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 6.270467e-01 | 0.203 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 6.270467e-01 | 0.203 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 6.270467e-01 | 0.203 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 6.270467e-01 | 0.203 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 6.270467e-01 | 0.203 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 6.270467e-01 | 0.203 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 6.276531e-01 | 0.202 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 6.311484e-01 | 0.200 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 6.311484e-01 | 0.200 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 6.311484e-01 | 0.200 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 6.311484e-01 | 0.200 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 6.311484e-01 | 0.200 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 6.365076e-01 | 0.196 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 6.440008e-01 | 0.191 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 6.440008e-01 | 0.191 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 6.440008e-01 | 0.191 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 6.440008e-01 | 0.191 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 6.440008e-01 | 0.191 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 6.440008e-01 | 0.191 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 6.440008e-01 | 0.191 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 6.440008e-01 | 0.191 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 6.440008e-01 | 0.191 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 6.440008e-01 | 0.191 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 6.440008e-01 | 0.191 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 6.440008e-01 | 0.191 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 6.440008e-01 | 0.191 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 6.462941e-01 | 0.190 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 6.462941e-01 | 0.190 | 0 | 0 |
| Highly sodium permeable postsynaptic acetylcholine nicotinic receptors | R-HSA-629587 | 6.462941e-01 | 0.190 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 6.462941e-01 | 0.190 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 6.462941e-01 | 0.190 | 0 | 0 |
| NADPH regeneration | R-HSA-389542 | 6.462941e-01 | 0.190 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 6.462941e-01 | 0.190 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 6.492397e-01 | 0.188 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 6.492397e-01 | 0.188 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 6.492397e-01 | 0.188 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 6.503389e-01 | 0.187 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 6.503389e-01 | 0.187 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 6.503389e-01 | 0.187 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 6.536414e-01 | 0.185 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 6.536414e-01 | 0.185 | 1 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 6.584039e-01 | 0.182 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 6.584039e-01 | 0.182 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 6.596292e-01 | 0.181 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 6.646950e-01 | 0.177 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 6.655052e-01 | 0.177 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 6.667589e-01 | 0.176 | 1 | 1 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 6.667589e-01 | 0.176 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 6.706981e-01 | 0.173 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 6.706981e-01 | 0.173 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 6.713765e-01 | 0.173 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 6.713765e-01 | 0.173 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 6.713765e-01 | 0.173 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 6.713765e-01 | 0.173 | 0 | 0 |
| Regulation of BACH1 activity | R-HSA-9708530 | 6.713765e-01 | 0.173 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 6.713765e-01 | 0.173 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 6.713765e-01 | 0.173 | 0 | 0 |
| Serotonin and melatonin biosynthesis | R-HSA-209931 | 6.713765e-01 | 0.173 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 6.713765e-01 | 0.173 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 6.713765e-01 | 0.173 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 6.713765e-01 | 0.173 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 6.713765e-01 | 0.173 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 6.725733e-01 | 0.172 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 6.725733e-01 | 0.172 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 6.725733e-01 | 0.172 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 6.775090e-01 | 0.169 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 6.848800e-01 | 0.164 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 6.848800e-01 | 0.164 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 6.848800e-01 | 0.164 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 6.848800e-01 | 0.164 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 6.848800e-01 | 0.164 | 0 | 0 |
| mRNA Editing: C to U Conversion | R-HSA-72200 | 6.848800e-01 | 0.164 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 6.848800e-01 | 0.164 | 0 | 0 |
| Activation of TRKA receptors | R-HSA-187015 | 6.848800e-01 | 0.164 | 0 | 0 |
| Glycoprotein hormones | R-HSA-209822 | 6.848800e-01 | 0.164 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 6.848800e-01 | 0.164 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 6.848800e-01 | 0.164 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 6.848800e-01 | 0.164 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 6.902959e-01 | 0.161 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 6.902959e-01 | 0.161 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 6.902959e-01 | 0.161 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 6.905743e-01 | 0.161 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 6.905743e-01 | 0.161 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 6.905743e-01 | 0.161 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 6.937491e-01 | 0.159 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 6.937491e-01 | 0.159 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 6.937491e-01 | 0.159 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 6.958564e-01 | 0.157 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 6.958564e-01 | 0.157 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 6.958564e-01 | 0.157 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 6.970183e-01 | 0.157 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 6.970183e-01 | 0.157 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 6.970183e-01 | 0.157 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 6.970183e-01 | 0.157 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 6.970183e-01 | 0.157 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 6.989572e-01 | 0.156 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 7.000409e-01 | 0.155 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 7.000409e-01 | 0.155 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 7.014131e-01 | 0.154 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 7.014131e-01 | 0.154 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 7.046223e-01 | 0.152 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 7.138731e-01 | 0.146 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 7.181343e-01 | 0.144 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 7.192587e-01 | 0.143 | 0 | 0 |
| Activation of RAS in B cells | R-HSA-1169092 | 7.192587e-01 | 0.143 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 7.192587e-01 | 0.143 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 7.192587e-01 | 0.143 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 7.192587e-01 | 0.143 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 7.192587e-01 | 0.143 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 7.192587e-01 | 0.143 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 7.192587e-01 | 0.143 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 7.192587e-01 | 0.143 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 7.192587e-01 | 0.143 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 7.192587e-01 | 0.143 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 7.192587e-01 | 0.143 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 7.192587e-01 | 0.143 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 7.194665e-01 | 0.143 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 7.194665e-01 | 0.143 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 7.194665e-01 | 0.143 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 7.198256e-01 | 0.143 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 7.209788e-01 | 0.142 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 7.209788e-01 | 0.142 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 7.209788e-01 | 0.142 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 7.209788e-01 | 0.142 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 7.209788e-01 | 0.142 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 7.209788e-01 | 0.142 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 7.209788e-01 | 0.142 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 7.209788e-01 | 0.142 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 7.209788e-01 | 0.142 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 7.219657e-01 | 0.141 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 7.237342e-01 | 0.140 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 7.302732e-01 | 0.137 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 7.302732e-01 | 0.137 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 7.309472e-01 | 0.136 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 7.309472e-01 | 0.136 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 7.309472e-01 | 0.136 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 7.329589e-01 | 0.135 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 7.329589e-01 | 0.135 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 7.329589e-01 | 0.135 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 7.329589e-01 | 0.135 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 7.433194e-01 | 0.129 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 7.433194e-01 | 0.129 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 7.433194e-01 | 0.129 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 7.433194e-01 | 0.129 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 7.433194e-01 | 0.129 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 7.445131e-01 | 0.128 | 1 | 1 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 7.455076e-01 | 0.128 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 7.455076e-01 | 0.128 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 7.455076e-01 | 0.128 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 7.463504e-01 | 0.127 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 7.463504e-01 | 0.127 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 7.466735e-01 | 0.127 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 7.466735e-01 | 0.127 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 7.498885e-01 | 0.125 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 7.498885e-01 | 0.125 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 7.498885e-01 | 0.125 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 7.498885e-01 | 0.125 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 7.498885e-01 | 0.125 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 7.498885e-01 | 0.125 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 7.498885e-01 | 0.125 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 7.498885e-01 | 0.125 | 0 | 0 |
| mRNA Editing | R-HSA-75072 | 7.498885e-01 | 0.125 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 7.498885e-01 | 0.125 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 7.498885e-01 | 0.125 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 7.498885e-01 | 0.125 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 7.498885e-01 | 0.125 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 7.498885e-01 | 0.125 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 7.501416e-01 | 0.125 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 7.510256e-01 | 0.124 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 7.510256e-01 | 0.124 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 7.519634e-01 | 0.124 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 7.594770e-01 | 0.119 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 7.594770e-01 | 0.119 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 7.641085e-01 | 0.117 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 7.641085e-01 | 0.117 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 7.641085e-01 | 0.117 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 7.641085e-01 | 0.117 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 7.648135e-01 | 0.116 | 1 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 7.648135e-01 | 0.116 | 1 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 7.650625e-01 | 0.116 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 7.658768e-01 | 0.116 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 7.666481e-01 | 0.115 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 7.680971e-01 | 0.115 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 7.680971e-01 | 0.115 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 7.680971e-01 | 0.115 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 7.680971e-01 | 0.115 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 7.680971e-01 | 0.115 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.689394e-01 | 0.114 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 7.719208e-01 | 0.112 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 7.719208e-01 | 0.112 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 7.737996e-01 | 0.111 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 7.771781e-01 | 0.109 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 7.771781e-01 | 0.109 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 7.771781e-01 | 0.109 | 0 | 0 |
| TET1,2,3 and TDG demethylate DNA | R-HSA-5221030 | 7.771781e-01 | 0.109 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 7.771781e-01 | 0.109 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 7.771781e-01 | 0.109 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 7.771781e-01 | 0.109 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 7.771781e-01 | 0.109 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 7.771781e-01 | 0.109 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 7.771781e-01 | 0.109 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 7.771781e-01 | 0.109 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 7.771781e-01 | 0.109 | 0 | 0 |
| Peptide hormone biosynthesis | R-HSA-209952 | 7.771781e-01 | 0.109 | 0 | 0 |
| Metal sequestration by antimicrobial proteins | R-HSA-6799990 | 7.771781e-01 | 0.109 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 7.791024e-01 | 0.108 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 7.834185e-01 | 0.106 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 7.834185e-01 | 0.106 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 7.834185e-01 | 0.106 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 7.838180e-01 | 0.106 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 7.838180e-01 | 0.106 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 7.842010e-01 | 0.106 | 0 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 7.842010e-01 | 0.106 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 7.856680e-01 | 0.105 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 7.856680e-01 | 0.105 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 7.901747e-01 | 0.102 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 7.901747e-01 | 0.102 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 7.901747e-01 | 0.102 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 7.901747e-01 | 0.102 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 7.901747e-01 | 0.102 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 7.943063e-01 | 0.100 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 7.945128e-01 | 0.100 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 7.979069e-01 | 0.098 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 7.979069e-01 | 0.098 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 7.989059e-01 | 0.098 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 7.993679e-01 | 0.097 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 7.993679e-01 | 0.097 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.002502e-01 | 0.097 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 8.013247e-01 | 0.096 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 8.013247e-01 | 0.096 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 8.013247e-01 | 0.096 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 8.013247e-01 | 0.096 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 8.013247e-01 | 0.096 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 8.013247e-01 | 0.096 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 8.013247e-01 | 0.096 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 8.013247e-01 | 0.096 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 8.014915e-01 | 0.096 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 8.014915e-01 | 0.096 | 0 | 0 |
| FGFR2b ligand binding and activation | R-HSA-190377 | 8.014915e-01 | 0.096 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 8.014915e-01 | 0.096 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 8.014915e-01 | 0.096 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 8.014915e-01 | 0.096 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 8.014915e-01 | 0.096 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 8.014915e-01 | 0.096 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 8.014915e-01 | 0.096 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 8.014915e-01 | 0.096 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 8.014915e-01 | 0.096 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 8.014915e-01 | 0.096 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 8.014915e-01 | 0.096 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 8.014915e-01 | 0.096 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 8.014915e-01 | 0.096 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 8.025370e-01 | 0.096 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 8.061884e-01 | 0.094 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 8.095888e-01 | 0.092 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 8.136308e-01 | 0.090 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 8.158682e-01 | 0.088 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 8.158682e-01 | 0.088 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 8.158682e-01 | 0.088 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 8.158682e-01 | 0.088 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 8.158682e-01 | 0.088 | 1 | 1 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 8.166767e-01 | 0.088 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 8.168361e-01 | 0.088 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 8.179034e-01 | 0.087 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 8.179034e-01 | 0.087 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 8.179034e-01 | 0.087 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 8.179034e-01 | 0.087 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 8.231533e-01 | 0.085 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by WNT ligand antagonists | R-HSA-3772470 | 8.231533e-01 | 0.085 | 0 | 0 |
| Presynaptic nicotinic acetylcholine receptors | R-HSA-622323 | 8.231533e-01 | 0.085 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 8.231533e-01 | 0.085 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 8.231533e-01 | 0.085 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 8.231533e-01 | 0.085 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 8.231533e-01 | 0.085 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 8.231533e-01 | 0.085 | 0 | 0 |
| Uptake of dietary cobalamins into enterocytes | R-HSA-9758881 | 8.231533e-01 | 0.085 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 8.308373e-01 | 0.080 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 8.310636e-01 | 0.080 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 8.328331e-01 | 0.079 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 8.332311e-01 | 0.079 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 8.332311e-01 | 0.079 | 0 | 0 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 8.332311e-01 | 0.079 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 8.332311e-01 | 0.079 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 8.387088e-01 | 0.076 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 8.389183e-01 | 0.076 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 8.391145e-01 | 0.076 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 8.395845e-01 | 0.076 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 8.395845e-01 | 0.076 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 8.424524e-01 | 0.074 | 0 | 0 |
| Defective EXT2 causes exostoses 2 | R-HSA-3656237 | 8.424524e-01 | 0.074 | 0 | 0 |
| Defective EXT1 causes exostoses 1, TRPS2 and CHDS | R-HSA-3656253 | 8.424524e-01 | 0.074 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 8.424524e-01 | 0.074 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 8.424524e-01 | 0.074 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 8.424524e-01 | 0.074 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 8.424524e-01 | 0.074 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 8.424524e-01 | 0.074 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 8.424524e-01 | 0.074 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 8.424524e-01 | 0.074 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 8.424524e-01 | 0.074 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 8.424524e-01 | 0.074 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 8.424524e-01 | 0.074 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 8.424524e-01 | 0.074 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 8.473833e-01 | 0.072 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 8.473833e-01 | 0.072 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 8.473833e-01 | 0.072 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 8.473833e-01 | 0.072 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 8.473833e-01 | 0.072 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 8.495054e-01 | 0.071 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 8.495054e-01 | 0.071 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 8.510068e-01 | 0.070 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 8.510068e-01 | 0.070 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 8.513480e-01 | 0.070 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 8.513480e-01 | 0.070 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 8.513480e-01 | 0.070 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 8.538172e-01 | 0.069 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 8.550880e-01 | 0.068 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 8.554447e-01 | 0.068 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 8.594973e-01 | 0.066 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 8.594973e-01 | 0.066 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 8.594973e-01 | 0.066 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 8.596464e-01 | 0.066 | 0 | 0 |
| FGFR2c ligand binding and activation | R-HSA-190375 | 8.596464e-01 | 0.066 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 8.596464e-01 | 0.066 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 8.596464e-01 | 0.066 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 8.596464e-01 | 0.066 | 0 | 0 |
| Postsynaptic nicotinic acetylcholine receptors | R-HSA-622327 | 8.596464e-01 | 0.066 | 0 | 0 |
| Acetylcholine binding and downstream events | R-HSA-181431 | 8.596464e-01 | 0.066 | 0 | 0 |
| Signaling by activated point mutants of FGFR3 | R-HSA-1839130 | 8.596464e-01 | 0.066 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 8.596464e-01 | 0.066 | 0 | 0 |
| Mtb iron assimilation by chelation | R-HSA-1222449 | 8.596464e-01 | 0.066 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 8.596464e-01 | 0.066 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 8.596464e-01 | 0.066 | 0 | 0 |
| FGFR3 mutant receptor activation | R-HSA-2033514 | 8.596464e-01 | 0.066 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 8.596464e-01 | 0.066 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 8.596464e-01 | 0.066 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 8.596464e-01 | 0.066 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 8.596464e-01 | 0.066 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 8.596464e-01 | 0.066 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 8.596464e-01 | 0.066 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 8.601067e-01 | 0.065 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 8.604340e-01 | 0.065 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 8.604340e-01 | 0.065 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 8.604340e-01 | 0.065 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 8.623518e-01 | 0.064 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 8.623518e-01 | 0.064 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 8.625647e-01 | 0.064 | 1 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 8.628303e-01 | 0.064 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 8.635309e-01 | 0.064 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 8.660500e-01 | 0.062 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 8.689170e-01 | 0.061 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 8.689170e-01 | 0.061 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 8.689170e-01 | 0.061 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 8.704625e-01 | 0.060 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 8.707835e-01 | 0.060 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 8.712755e-01 | 0.060 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 8.724549e-01 | 0.059 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 8.724549e-01 | 0.059 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 8.724549e-01 | 0.059 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 8.726329e-01 | 0.059 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 8.726329e-01 | 0.059 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 8.738315e-01 | 0.059 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 8.749648e-01 | 0.058 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 8.749648e-01 | 0.058 | 0 | 0 |
| FGFR3c ligand binding and activation | R-HSA-190372 | 8.749648e-01 | 0.058 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 8.749648e-01 | 0.058 | 0 | 0 |
| Prolactin receptor signaling | R-HSA-1170546 | 8.749648e-01 | 0.058 | 0 | 0 |
| Glycerophospholipid catabolism | R-HSA-6814848 | 8.749648e-01 | 0.058 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 8.749648e-01 | 0.058 | 0 | 0 |
| Ciprofloxacin ADME | R-HSA-9793528 | 8.749648e-01 | 0.058 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 8.749648e-01 | 0.058 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 8.749648e-01 | 0.058 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 8.749648e-01 | 0.058 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 8.777879e-01 | 0.057 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 8.777879e-01 | 0.057 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 8.785088e-01 | 0.056 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 8.794209e-01 | 0.056 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 8.802487e-01 | 0.055 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 8.810717e-01 | 0.055 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 8.822281e-01 | 0.054 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 8.831653e-01 | 0.054 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 8.835154e-01 | 0.054 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 8.835154e-01 | 0.054 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 8.835154e-01 | 0.054 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 8.835154e-01 | 0.054 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 8.835154e-01 | 0.054 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 8.835154e-01 | 0.054 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 8.835154e-01 | 0.054 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 8.835154e-01 | 0.054 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 8.835154e-01 | 0.054 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 8.861337e-01 | 0.053 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 8.869084e-01 | 0.052 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 8.869084e-01 | 0.052 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 8.883768e-01 | 0.051 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 8.886122e-01 | 0.051 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 8.886122e-01 | 0.051 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 8.886122e-01 | 0.051 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 8.886122e-01 | 0.051 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 8.886122e-01 | 0.051 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 8.886122e-01 | 0.051 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 8.886122e-01 | 0.051 | 0 | 0 |
| FGFR3 ligand binding and activation | R-HSA-190239 | 8.886122e-01 | 0.051 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.886122e-01 | 0.051 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.887172e-01 | 0.051 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 8.893630e-01 | 0.051 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 8.907214e-01 | 0.050 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 8.919666e-01 | 0.050 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 8.919928e-01 | 0.050 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.936819e-01 | 0.049 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 8.936819e-01 | 0.049 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 8.936819e-01 | 0.049 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 8.936819e-01 | 0.049 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 8.936819e-01 | 0.049 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 8.939775e-01 | 0.049 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 8.952841e-01 | 0.048 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 8.960150e-01 | 0.048 | 1 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 8.960150e-01 | 0.048 | 1 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 8.977932e-01 | 0.047 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 8.984578e-01 | 0.047 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 8.995050e-01 | 0.046 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 9.007707e-01 | 0.045 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 9.007707e-01 | 0.045 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 9.007707e-01 | 0.045 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 9.007707e-01 | 0.045 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 9.007707e-01 | 0.045 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 9.007707e-01 | 0.045 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 9.009369e-01 | 0.045 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 9.030176e-01 | 0.044 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 9.030176e-01 | 0.044 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 9.036657e-01 | 0.044 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 9.050470e-01 | 0.043 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 9.054057e-01 | 0.043 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.063299e-01 | 0.043 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 9.072568e-01 | 0.042 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.078206e-01 | 0.042 | 1 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 9.082521e-01 | 0.042 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 9.115828e-01 | 0.040 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 9.115828e-01 | 0.040 | 0 | 0 |
| Defective B3GALT6 causes EDSP2 and SEMDJL1 | R-HSA-4420332 | 9.116026e-01 | 0.040 | 0 | 0 |
| Defective B4GALT7 causes EDS, progeroid type | R-HSA-3560783 | 9.116026e-01 | 0.040 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 9.116026e-01 | 0.040 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 9.116026e-01 | 0.040 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 9.116026e-01 | 0.040 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 9.116026e-01 | 0.040 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 9.116026e-01 | 0.040 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 9.116026e-01 | 0.040 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 9.144627e-01 | 0.039 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 9.158962e-01 | 0.038 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 9.194344e-01 | 0.036 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 9.194344e-01 | 0.036 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 9.207929e-01 | 0.036 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 9.207929e-01 | 0.036 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 9.207929e-01 | 0.036 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 9.211220e-01 | 0.036 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 9.211550e-01 | 0.036 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 9.212527e-01 | 0.036 | 0 | 0 |
| Defective B3GAT3 causes JDSSDHD | R-HSA-3560801 | 9.212527e-01 | 0.036 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 9.212527e-01 | 0.036 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 9.212527e-01 | 0.036 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 9.212527e-01 | 0.036 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 9.212527e-01 | 0.036 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 9.212527e-01 | 0.036 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 9.212527e-01 | 0.036 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 9.212527e-01 | 0.036 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.228241e-01 | 0.035 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.241119e-01 | 0.034 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 9.266261e-01 | 0.033 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 9.266261e-01 | 0.033 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 9.298499e-01 | 0.032 | 0 | 0 |
| Activated point mutants of FGFR2 | R-HSA-2033519 | 9.298499e-01 | 0.032 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 9.298499e-01 | 0.032 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 9.298499e-01 | 0.032 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 9.298499e-01 | 0.032 | 0 | 0 |
| Organic anion transport by SLC5/17/25 transporters | R-HSA-428643 | 9.298499e-01 | 0.032 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 9.298499e-01 | 0.032 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 9.298499e-01 | 0.032 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 9.321127e-01 | 0.031 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.327968e-01 | 0.030 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 9.331230e-01 | 0.030 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 9.337052e-01 | 0.030 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.360642e-01 | 0.029 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.367305e-01 | 0.028 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 9.371722e-01 | 0.028 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 9.373376e-01 | 0.028 | 0 | 0 |
| Pyrimidine biosynthesis | R-HSA-500753 | 9.375089e-01 | 0.028 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 9.375089e-01 | 0.028 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 9.375089e-01 | 0.028 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 9.375089e-01 | 0.028 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 9.375089e-01 | 0.028 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 9.375089e-01 | 0.028 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 9.375089e-01 | 0.028 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 9.384574e-01 | 0.028 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 9.384574e-01 | 0.028 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 9.391913e-01 | 0.027 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 9.392285e-01 | 0.027 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 9.405841e-01 | 0.027 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 9.424414e-01 | 0.026 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 9.443321e-01 | 0.025 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 9.443321e-01 | 0.025 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 9.443321e-01 | 0.025 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 9.443321e-01 | 0.025 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 9.447307e-01 | 0.025 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.447307e-01 | 0.025 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 9.447307e-01 | 0.025 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 9.447307e-01 | 0.025 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 9.456747e-01 | 0.024 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 9.457207e-01 | 0.024 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 9.471853e-01 | 0.024 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 9.478153e-01 | 0.023 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.496988e-01 | 0.022 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 9.497564e-01 | 0.022 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 9.497564e-01 | 0.022 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.502327e-01 | 0.022 | 0 | 0 |
| FGFR2 ligand binding and activation | R-HSA-190241 | 9.504106e-01 | 0.022 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 9.504106e-01 | 0.022 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 9.504106e-01 | 0.022 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 9.504106e-01 | 0.022 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 9.504106e-01 | 0.022 | 0 | 0 |
| Synthesis, secretion, and deacylation of Ghrelin | R-HSA-422085 | 9.504106e-01 | 0.022 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 9.504106e-01 | 0.022 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 9.515265e-01 | 0.022 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.534475e-01 | 0.021 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.535446e-01 | 0.021 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.543439e-01 | 0.020 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 9.543439e-01 | 0.020 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 9.558257e-01 | 0.020 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 9.558257e-01 | 0.020 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 9.560876e-01 | 0.020 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 9.569372e-01 | 0.019 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 9.585290e-01 | 0.018 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 9.585290e-01 | 0.018 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 9.592366e-01 | 0.018 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 9.594347e-01 | 0.018 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 9.596889e-01 | 0.018 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 9.601839e-01 | 0.018 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 9.606498e-01 | 0.017 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 9.606498e-01 | 0.017 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 9.606498e-01 | 0.017 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 9.606498e-01 | 0.017 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 9.606498e-01 | 0.017 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.621169e-01 | 0.017 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 9.623448e-01 | 0.017 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 9.623448e-01 | 0.017 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.623448e-01 | 0.017 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.623448e-01 | 0.017 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 9.648091e-01 | 0.016 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.649473e-01 | 0.015 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 9.649473e-01 | 0.015 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 9.649473e-01 | 0.015 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 9.649473e-01 | 0.015 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 9.649473e-01 | 0.015 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.649473e-01 | 0.015 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.649473e-01 | 0.015 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.658222e-01 | 0.015 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 9.660073e-01 | 0.015 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 9.687757e-01 | 0.014 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 9.687757e-01 | 0.014 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 9.687757e-01 | 0.014 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 9.687757e-01 | 0.014 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 9.687757e-01 | 0.014 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.688976e-01 | 0.014 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 9.713926e-01 | 0.013 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 9.718727e-01 | 0.012 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 9.720125e-01 | 0.012 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 9.720125e-01 | 0.012 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 9.720125e-01 | 0.012 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 9.721862e-01 | 0.012 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 9.721862e-01 | 0.012 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 9.721862e-01 | 0.012 | 0 | 0 |
| Alpha-oxidation of phytanate | R-HSA-389599 | 9.721862e-01 | 0.012 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 9.721862e-01 | 0.012 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.721862e-01 | 0.012 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 9.721862e-01 | 0.012 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.744963e-01 | 0.011 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 9.744963e-01 | 0.011 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 9.752243e-01 | 0.011 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 9.752243e-01 | 0.011 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 9.752243e-01 | 0.011 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.752243e-01 | 0.011 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.752243e-01 | 0.011 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.753504e-01 | 0.011 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 9.755125e-01 | 0.011 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 9.768826e-01 | 0.010 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 9.769375e-01 | 0.010 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 9.779308e-01 | 0.010 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 9.779308e-01 | 0.010 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 9.779308e-01 | 0.010 | 0 | 0 |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | R-HSA-193807 | 9.779308e-01 | 0.010 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 9.779308e-01 | 0.010 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 9.781155e-01 | 0.010 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 9.783371e-01 | 0.010 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 9.790516e-01 | 0.009 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.790521e-01 | 0.009 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.790521e-01 | 0.009 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.800245e-01 | 0.009 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 9.803417e-01 | 0.009 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 9.803417e-01 | 0.009 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 9.803417e-01 | 0.009 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 9.804674e-01 | 0.009 | 0 | 0 |
| Defensins | R-HSA-1461973 | 9.810236e-01 | 0.008 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 9.812562e-01 | 0.008 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.814957e-01 | 0.008 | 1 | 1 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 9.822389e-01 | 0.008 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.824894e-01 | 0.008 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 9.824894e-01 | 0.008 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 9.824894e-01 | 0.008 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 9.824894e-01 | 0.008 | 0 | 0 |
| Activation of Matrix Metalloproteinases | R-HSA-1592389 | 9.824894e-01 | 0.008 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 9.826499e-01 | 0.008 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 9.830618e-01 | 0.007 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 9.832530e-01 | 0.007 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 9.839683e-01 | 0.007 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 9.844026e-01 | 0.007 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 9.844026e-01 | 0.007 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 9.844408e-01 | 0.007 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 9.844408e-01 | 0.007 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 9.854379e-01 | 0.006 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.857633e-01 | 0.006 | 1 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 9.859169e-01 | 0.006 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.860131e-01 | 0.006 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 9.860131e-01 | 0.006 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 9.861068e-01 | 0.006 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 9.861068e-01 | 0.006 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 9.861068e-01 | 0.006 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 9.861068e-01 | 0.006 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 9.861068e-01 | 0.006 | 0 | 0 |
| Synthesis of glycosylphosphatidylinositol (GPI) | R-HSA-162710 | 9.861068e-01 | 0.006 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 9.861632e-01 | 0.006 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 9.872239e-01 | 0.006 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 9.872239e-01 | 0.006 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 9.872564e-01 | 0.006 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 9.874991e-01 | 0.005 | 1 | 0 |
| HS-GAG degradation | R-HSA-2024096 | 9.876249e-01 | 0.005 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 9.884714e-01 | 0.005 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 9.889772e-01 | 0.005 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 9.889772e-01 | 0.005 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.889772e-01 | 0.005 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.889772e-01 | 0.005 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 9.891394e-01 | 0.005 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 9.892537e-01 | 0.005 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.892537e-01 | 0.005 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 9.892537e-01 | 0.005 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 9.892537e-01 | 0.005 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.894318e-01 | 0.005 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 9.895731e-01 | 0.005 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 9.895731e-01 | 0.005 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 9.901285e-01 | 0.004 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 9.901818e-01 | 0.004 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.901818e-01 | 0.004 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 9.901818e-01 | 0.004 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 9.908170e-01 | 0.004 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 9.909350e-01 | 0.004 | 0 | 0 |
| Glycosaminoglycan-protein linkage region biosynthesis | R-HSA-1971475 | 9.912548e-01 | 0.004 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 9.912548e-01 | 0.004 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 9.912548e-01 | 0.004 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 9.912548e-01 | 0.004 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 9.912548e-01 | 0.004 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.912644e-01 | 0.004 | 1 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 9.914768e-01 | 0.004 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.918628e-01 | 0.004 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 9.919133e-01 | 0.004 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.920093e-01 | 0.003 | 1 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.920127e-01 | 0.003 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 9.922106e-01 | 0.003 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 9.922106e-01 | 0.003 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 9.922106e-01 | 0.003 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.922106e-01 | 0.003 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 9.922106e-01 | 0.003 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 9.922106e-01 | 0.003 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 9.922967e-01 | 0.003 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 9.927190e-01 | 0.003 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.929932e-01 | 0.003 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 9.930392e-01 | 0.003 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.930392e-01 | 0.003 | 0 | 0 |
| HS-GAG biosynthesis | R-HSA-2022928 | 9.930620e-01 | 0.003 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 9.930620e-01 | 0.003 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.930620e-01 | 0.003 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 9.931821e-01 | 0.003 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.932659e-01 | 0.003 | 1 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.932659e-01 | 0.003 | 1 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 9.937115e-01 | 0.003 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 9.938204e-01 | 0.003 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 9.938204e-01 | 0.003 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 9.938204e-01 | 0.003 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.938752e-01 | 0.003 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.938752e-01 | 0.003 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 9.943201e-01 | 0.002 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 9.943201e-01 | 0.002 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.944201e-01 | 0.002 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 9.944959e-01 | 0.002 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 9.944959e-01 | 0.002 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 9.944959e-01 | 0.002 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 9.948707e-01 | 0.002 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.950500e-01 | 0.002 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.950705e-01 | 0.002 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 9.950976e-01 | 0.002 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.950976e-01 | 0.002 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 9.950976e-01 | 0.002 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 9.950976e-01 | 0.002 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 9.953690e-01 | 0.002 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.953690e-01 | 0.002 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.953690e-01 | 0.002 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 9.956336e-01 | 0.002 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 9.961110e-01 | 0.002 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 9.961110e-01 | 0.002 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 9.961110e-01 | 0.002 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.961658e-01 | 0.002 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.962271e-01 | 0.002 | 0 | 0 |
| Immune System | R-HSA-168256 | 9.962335e-01 | 0.002 | 1 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 9.963678e-01 | 0.002 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.965183e-01 | 0.002 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 9.965362e-01 | 0.002 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 9.965362e-01 | 0.002 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 9.965954e-01 | 0.001 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.966299e-01 | 0.001 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 9.967758e-01 | 0.001 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 9.968263e-01 | 0.001 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.969150e-01 | 0.001 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 9.969150e-01 | 0.001 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.969284e-01 | 0.001 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.971135e-01 | 0.001 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 9.972523e-01 | 0.001 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 9.972523e-01 | 0.001 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.973331e-01 | 0.001 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.975528e-01 | 0.001 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 9.975528e-01 | 0.001 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 9.975528e-01 | 0.001 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.977701e-01 | 0.001 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 9.978205e-01 | 0.001 | 0 | 0 |
| Diseases associated with glycosaminoglycan metabolism | R-HSA-3560782 | 9.978205e-01 | 0.001 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 9.978205e-01 | 0.001 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.978964e-01 | 0.001 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.980588e-01 | 0.001 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.981196e-01 | 0.001 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.981686e-01 | 0.001 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.982307e-01 | 0.001 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 9.982384e-01 | 0.001 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 9.982712e-01 | 0.001 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 9.982712e-01 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 9.983493e-01 | 0.001 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.983493e-01 | 0.001 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.984603e-01 | 0.001 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.985124e-01 | 0.001 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.986120e-01 | 0.001 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 9.986287e-01 | 0.001 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 9.988953e-01 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.989122e-01 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 9.989122e-01 | 0.000 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.989122e-01 | 0.000 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.989123e-01 | 0.000 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.989123e-01 | 0.000 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.990202e-01 | 0.000 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.991150e-01 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.992055e-01 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.992457e-01 | 0.000 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.993158e-01 | 0.000 | 0 | 0 |
| Protein folding | R-HSA-391251 | 9.993848e-01 | 0.000 | 0 | 0 |
| Digestion | R-HSA-8935690 | 9.993907e-01 | 0.000 | 0 | 0 |
| Heparan sulfate/heparin (HS-GAG) metabolism | R-HSA-1638091 | 9.995696e-01 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.995942e-01 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 9.996098e-01 | 0.000 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.996168e-01 | 0.000 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 9.996168e-01 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 9.996200e-01 | 0.000 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 9.996486e-01 | 0.000 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 9.996587e-01 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.997208e-01 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.997293e-01 | 0.000 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 9.997472e-01 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.997590e-01 | 0.000 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.997716e-01 | 0.000 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.997781e-01 | 0.000 | 0 | 0 |
| Latent infection - Other responses of Mtb to phagocytosis | R-HSA-1222499 | 9.997854e-01 | 0.000 | 0 | 0 |
| Class C/3 (Metabotropic glutamate/pheromone receptors) | R-HSA-420499 | 9.998375e-01 | 0.000 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 9.998540e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.998598e-01 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 9.998930e-01 | 0.000 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 9.998973e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.999151e-01 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.999161e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999173e-01 | 0.000 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.999327e-01 | 0.000 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 9.999368e-01 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.999443e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.999443e-01 | 0.000 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 9.999516e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.999525e-01 | 0.000 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 9.999551e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.999551e-01 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.999587e-01 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.999648e-01 | 0.000 | 1 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.999665e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.999738e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.999763e-01 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 9.999782e-01 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 9.999789e-01 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.999851e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.999877e-01 | 0.000 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.999895e-01 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 9.999904e-01 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.999914e-01 | 0.000 | 1 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999934e-01 | 0.000 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.999936e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.999963e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999969e-01 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.999973e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999993e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999997e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999998e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999999e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999999e-01 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.999999e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999999e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999999e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.999999e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 1.000000e+00 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000e+00 | 0.000 | 1 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000e+00 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000e+00 | 0.000 | 1 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000e+00 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000e+00 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000e+00 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000e+00 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000e+00 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 1.000000e+00 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000e+00 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000e+00 | 0.000 | 1 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 1.000000e+00 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 1 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 1 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Apoptotic execution phase | R-HSA-75153 | 0.000004 | 5.423 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.000005 | 5.333 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 0.000004 | 5.351 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.000007 | 5.136 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 0.000013 | 4.873 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 0.000017 | 4.780 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.000030 | 4.523 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.000030 | 4.527 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 0.000037 | 4.437 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.000036 | 4.442 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 0.000075 | 4.123 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.000079 | 4.101 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 0.000089 | 4.050 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 0.000087 | 4.063 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 0.000113 | 3.947 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 0.000130 | 3.886 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 0.000135 | 3.869 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 0.000140 | 3.853 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 0.000144 | 3.843 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 0.000181 | 3.742 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.000172 | 3.765 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.000205 | 3.689 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 0.000226 | 3.646 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 0.000229 | 3.640 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 0.000229 | 3.640 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 0.000292 | 3.534 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 0.000292 | 3.534 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 0.000287 | 3.543 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 0.000294 | 3.532 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 0.000261 | 3.583 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 0.000287 | 3.543 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.000335 | 3.475 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.000337 | 3.473 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 0.000370 | 3.431 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.000385 | 3.415 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 0.000476 | 3.323 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.000473 | 3.325 | 1 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.000532 | 3.274 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 0.000574 | 3.241 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 0.000599 | 3.222 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.000712 | 3.148 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 0.000749 | 3.125 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.000833 | 3.079 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 0.000867 | 3.062 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.000908 | 3.042 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 0.000923 | 3.035 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 0.000929 | 3.032 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.001263 | 2.898 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.001302 | 2.885 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 0.001360 | 2.866 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 0.001469 | 2.833 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 0.001469 | 2.833 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 0.001507 | 2.822 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 0.002002 | 2.698 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.002298 | 2.639 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 0.002583 | 2.588 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 0.002583 | 2.588 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.002489 | 2.604 | 1 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.002587 | 2.587 | 1 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.002684 | 2.571 | 1 | 1 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 0.002933 | 2.533 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 0.003047 | 2.516 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 0.003393 | 2.469 | 0 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.003296 | 2.482 | 1 | 0 |
| CaM pathway | R-HSA-111997 | 0.003296 | 2.482 | 1 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 0.004091 | 2.388 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 0.004169 | 2.380 | 1 | 1 |
| Ca-dependent events | R-HSA-111996 | 0.004105 | 2.387 | 1 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 0.004232 | 2.373 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 0.004421 | 2.354 | 0 | 0 |
| RUNX1 regulates estrogen receptor mediated transcription | R-HSA-8931987 | 0.005239 | 2.281 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 0.005281 | 2.277 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.005207 | 2.283 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.005568 | 2.254 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.005339 | 2.273 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.005501 | 2.260 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.005908 | 2.229 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.006072 | 2.217 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.006072 | 2.217 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 0.006520 | 2.186 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 0.006542 | 2.184 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 0.006969 | 2.157 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 0.006969 | 2.157 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 0.007151 | 2.146 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.007244 | 2.140 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 0.007726 | 2.112 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 0.007726 | 2.112 | 1 | 1 |
| Signaling by VEGF | R-HSA-194138 | 0.007438 | 2.129 | 1 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 0.007742 | 2.111 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 0.008102 | 2.091 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.008154 | 2.089 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.008770 | 2.057 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 0.008995 | 2.046 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 0.008450 | 2.073 | 1 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 0.009135 | 2.039 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.009270 | 2.033 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 0.009797 | 2.009 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.010427 | 1.982 | 1 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 0.010427 | 1.982 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 0.010935 | 1.961 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.011529 | 1.938 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 0.011529 | 1.938 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.011545 | 1.938 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.011597 | 1.936 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 0.011830 | 1.927 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 0.011830 | 1.927 | 1 | 1 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 0.011983 | 1.921 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.012433 | 1.905 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.013530 | 1.869 | 1 | 0 |
| Axon guidance | R-HSA-422475 | 0.013113 | 1.882 | 1 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.013589 | 1.867 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.013589 | 1.867 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.013800 | 1.860 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 0.014043 | 1.853 | 1 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 0.014384 | 1.842 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 0.015467 | 1.811 | 1 | 1 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.015732 | 1.803 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.016687 | 1.778 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.016434 | 1.784 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.017111 | 1.767 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.017556 | 1.756 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.017556 | 1.756 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.017587 | 1.755 | 1 | 0 |
| RUNX1 regulates transcription of genes involved in WNT signaling | R-HSA-8939256 | 0.017870 | 1.748 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 0.017870 | 1.748 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 0.017882 | 1.748 | 1 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.019493 | 1.710 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.020316 | 1.692 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.020316 | 1.692 | 1 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.019681 | 1.706 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 0.019279 | 1.715 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 0.019279 | 1.715 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.018784 | 1.726 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 0.020605 | 1.686 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 0.020605 | 1.686 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 0.020605 | 1.686 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 0.020605 | 1.686 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 0.020605 | 1.686 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 0.020605 | 1.686 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.021815 | 1.661 | 1 | 1 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 0.022347 | 1.651 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.022349 | 1.651 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.022725 | 1.643 | 1 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 0.025047 | 1.601 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.024657 | 1.608 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 0.025695 | 1.590 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 0.025834 | 1.588 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 0.025834 | 1.588 | 1 | 1 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 0.026280 | 1.580 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 0.026280 | 1.580 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.026763 | 1.572 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.027333 | 1.563 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.027501 | 1.561 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 0.029417 | 1.531 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 0.030736 | 1.512 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.029802 | 1.526 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.029417 | 1.531 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 0.030668 | 1.513 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 0.030339 | 1.518 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.031948 | 1.496 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.031948 | 1.496 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 0.032375 | 1.490 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 0.032539 | 1.488 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 0.032539 | 1.488 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 0.032539 | 1.488 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 0.032539 | 1.488 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 0.032539 | 1.488 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 0.032968 | 1.482 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.033734 | 1.472 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 0.034042 | 1.468 | 1 | 1 |
| Striated Muscle Contraction | R-HSA-390522 | 0.034115 | 1.467 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.035021 | 1.456 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.035835 | 1.446 | 1 | 1 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 0.040894 | 1.388 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 0.038839 | 1.411 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 0.040894 | 1.388 | 1 | 1 |
| HATs acetylate histones | R-HSA-3214847 | 0.036946 | 1.432 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.037351 | 1.428 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 0.039455 | 1.404 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.039604 | 1.402 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.041573 | 1.381 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 0.042319 | 1.373 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 0.042326 | 1.373 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 0.042541 | 1.371 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 0.042541 | 1.371 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 0.042541 | 1.371 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.042789 | 1.369 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 0.043185 | 1.365 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 0.043185 | 1.365 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 0.043185 | 1.365 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 0.043185 | 1.365 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.043364 | 1.363 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 0.043968 | 1.357 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 0.046766 | 1.330 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 0.047039 | 1.328 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.044631 | 1.350 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.046089 | 1.336 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 0.046766 | 1.330 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 0.049363 | 1.307 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 0.049054 | 1.309 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 0.049054 | 1.309 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 0.049054 | 1.309 | 1 | 1 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 0.044682 | 1.350 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.050345 | 1.298 | 1 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.049577 | 1.305 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 0.049157 | 1.308 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 0.051225 | 1.291 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 0.051225 | 1.291 | 1 | 1 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.052178 | 1.283 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 0.054758 | 1.262 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 0.055752 | 1.254 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 0.055752 | 1.254 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 0.058421 | 1.233 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 0.058421 | 1.233 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 0.058421 | 1.233 | 1 | 1 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 0.058843 | 1.230 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 0.059378 | 1.226 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 0.059378 | 1.226 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.071561 | 1.145 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.071561 | 1.145 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 0.071561 | 1.145 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.071561 | 1.145 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.071561 | 1.145 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.071561 | 1.145 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.071561 | 1.145 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.071561 | 1.145 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.071561 | 1.145 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.071561 | 1.145 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.071561 | 1.145 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.071561 | 1.145 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 0.069064 | 1.161 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 0.069064 | 1.161 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 0.069064 | 1.161 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 0.069064 | 1.161 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 0.067569 | 1.170 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.069460 | 1.158 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 0.067569 | 1.170 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.067569 | 1.170 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 0.069064 | 1.161 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 0.062980 | 1.201 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 0.069460 | 1.158 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.072846 | 1.138 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 0.073122 | 1.136 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 0.075590 | 1.122 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.075617 | 1.121 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 0.076967 | 1.114 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 0.076967 | 1.114 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.077406 | 1.111 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 0.078402 | 1.106 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 0.078732 | 1.104 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.079316 | 1.101 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 0.082609 | 1.083 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.097742 | 1.010 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 0.097742 | 1.010 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 0.097742 | 1.010 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 0.083855 | 1.076 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 0.100057 | 1.000 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.100057 | 1.000 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 0.100057 | 1.000 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 0.100057 | 1.000 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 0.100057 | 1.000 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 0.100057 | 1.000 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 0.100057 | 1.000 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 0.100057 | 1.000 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 0.089396 | 1.049 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 0.092745 | 1.033 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.096898 | 1.014 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 0.083855 | 1.076 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 0.099468 | 1.002 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 0.087103 | 1.060 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 0.100057 | 1.000 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 0.086777 | 1.062 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 0.096898 | 1.014 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.098974 | 1.004 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 0.100057 | 1.000 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 0.083855 | 1.076 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 0.087103 | 1.060 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 0.091044 | 1.041 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.088257 | 1.054 | 1 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.101433 | 0.994 | 1 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 0.103071 | 0.987 | 0 | 0 |
| Drug resistance of PDGFR mutants | R-HSA-9674415 | 0.103371 | 0.986 | 0 | 0 |
| PDGFR mutants bind TKIs | R-HSA-9674428 | 0.103371 | 0.986 | 0 | 0 |
| Sunitinib-resistant PDGFR mutants | R-HSA-9674401 | 0.103371 | 0.986 | 0 | 0 |
| Deletions in the AXIN1 gene destabilize the destruction complex | R-HSA-5467345 | 0.103371 | 0.986 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 0.103371 | 0.986 | 0 | 0 |
| Regorafenib-resistant PDGFR mutants | R-HSA-9674403 | 0.103371 | 0.986 | 0 | 0 |
| Sorafenib-resistant PDGFR mutants | R-HSA-9674404 | 0.103371 | 0.986 | 0 | 0 |
| Imatinib-resistant PDGFR mutants | R-HSA-9674396 | 0.103371 | 0.986 | 0 | 0 |
| Signaling by FGFR1 amplification mutants | R-HSA-1839120 | 0.104296 | 0.982 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 0.104296 | 0.982 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 0.104296 | 0.982 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 0.104296 | 0.982 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 0.104296 | 0.982 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 0.104296 | 0.982 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 0.104757 | 0.980 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.104854 | 0.979 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 0.107848 | 0.967 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.109956 | 0.959 | 0 | 0 |
| PKA activation | R-HSA-163615 | 0.109956 | 0.959 | 1 | 1 |
| PKA activation in glucagon signalling | R-HSA-164378 | 0.109956 | 0.959 | 1 | 1 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 0.109956 | 0.959 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 0.109956 | 0.959 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 0.140186 | 0.853 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 0.140186 | 0.853 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 0.140186 | 0.853 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 0.140186 | 0.853 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 0.140186 | 0.853 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.136334 | 0.865 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 0.113743 | 0.944 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 0.135072 | 0.869 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.125157 | 0.903 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 0.120499 | 0.919 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 0.126210 | 0.899 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 0.126210 | 0.899 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.113126 | 0.946 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 0.119849 | 0.921 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.139246 | 0.856 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 0.125079 | 0.903 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.139626 | 0.855 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.136334 | 0.865 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.127049 | 0.896 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 0.113126 | 0.946 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.117875 | 0.929 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 0.139768 | 0.855 | 1 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.127786 | 0.894 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 0.125079 | 0.903 | 1 | 1 |
| L1CAM interactions | R-HSA-373760 | 0.126941 | 0.896 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.120499 | 0.919 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.127033 | 0.896 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 0.136334 | 0.865 | 1 | 1 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.140150 | 0.853 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 0.141070 | 0.851 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 0.141100 | 0.850 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.141456 | 0.849 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.141456 | 0.849 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 0.144980 | 0.839 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 0.144980 | 0.839 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 0.144980 | 0.839 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 0.146797 | 0.833 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 0.148938 | 0.827 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 0.151214 | 0.820 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.151731 | 0.819 | 0 | 0 |
| Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1) | R-HSA-5619043 | 0.196063 | 0.708 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 0.196063 | 0.708 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 0.196063 | 0.708 | 0 | 0 |
| Defective Mismatch Repair Associated With MLH1 | R-HSA-5545483 | 0.196063 | 0.708 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 0.196063 | 0.708 | 0 | 0 |
| TICAM1 deficiency - HSE | R-HSA-5602566 | 0.196063 | 0.708 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function | R-HSA-9645722 | 0.196063 | 0.708 | 0 | 0 |
| Defective Mismatch Repair Associated With PMS2 | R-HSA-5632987 | 0.196063 | 0.708 | 0 | 0 |
| TRAF3 deficiency - HSE | R-HSA-5602571 | 0.279176 | 0.554 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 0.279176 | 0.554 | 0 | 0 |
| Defective VWF binding to collagen type I | R-HSA-9845622 | 0.279176 | 0.554 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 0.279176 | 0.554 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 0.279176 | 0.554 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 0.279176 | 0.554 | 0 | 0 |
| Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3 | R-HSA-5083628 | 0.279176 | 0.554 | 0 | 0 |
| Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP) | R-HSA-5619053 | 0.279176 | 0.554 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 0.279176 | 0.554 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in BCR signaling | R-HSA-8939245 | 0.178230 | 0.749 | 0 | 0 |
| IRS activation | R-HSA-74713 | 0.178230 | 0.749 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 0.178230 | 0.749 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 0.178230 | 0.749 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 0.217599 | 0.662 | 0 | 0 |
| Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1 | R-HSA-5083633 | 0.353702 | 0.451 | 0 | 0 |
| Defective visual phototransduction due to RDH12 loss of function | R-HSA-9918440 | 0.353702 | 0.451 | 0 | 0 |
| Enhanced cleavage of VWF variant by ADAMTS13 | R-HSA-9845619 | 0.353702 | 0.451 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 0.353702 | 0.451 | 0 | 0 |
| Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2 | R-HSA-5083629 | 0.353702 | 0.451 | 0 | 0 |
| Defective VWF cleavage by ADAMTS13 variant | R-HSA-9845621 | 0.353702 | 0.451 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 0.170917 | 0.767 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 0.170917 | 0.767 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 0.170917 | 0.767 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 0.170917 | 0.767 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 0.257614 | 0.589 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 0.257614 | 0.589 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 0.257614 | 0.589 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 0.198046 | 0.703 | 0 | 0 |
| Activated NTRK3 signals through RAS | R-HSA-9034864 | 0.198046 | 0.703 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 0.156199 | 0.806 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 0.156199 | 0.806 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 0.177060 | 0.752 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.177060 | 0.752 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 0.177060 | 0.752 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 0.226111 | 0.646 | 0 | 0 |
| Activated NTRK2 signals through RAS | R-HSA-9026519 | 0.226111 | 0.646 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 0.226111 | 0.646 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 0.297721 | 0.526 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 0.297721 | 0.526 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 0.297721 | 0.526 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 0.297721 | 0.526 | 0 | 0 |
| The NLRP1 inflammasome | R-HSA-844455 | 0.420526 | 0.376 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 0.420526 | 0.376 | 0 | 0 |
| Signaling by plasma membrane FGFR1 fusions | R-HSA-8853336 | 0.420526 | 0.376 | 0 | 0 |
| Defective DPM3 causes DPM3-CDG | R-HSA-4719360 | 0.420526 | 0.376 | 0 | 0 |
| Defective DPM2 causes DPM2-CDG | R-HSA-4719377 | 0.420526 | 0.376 | 0 | 0 |
| Defective DPM1 causes DPM1-CDG | R-HSA-4717374 | 0.420526 | 0.376 | 0 | 0 |
| Defective ABCC2 causes DJS | R-HSA-5679001 | 0.420526 | 0.376 | 0 | 0 |
| Defective SLC7A7 causes lysinuric protein intolerance (LPI) | R-HSA-5660862 | 0.420526 | 0.376 | 0 | 0 |
| Defective gamma-carboxylation of F9 | R-HSA-9673240 | 0.420526 | 0.376 | 0 | 0 |
| 3-Methylcrotonyl-CoA carboxylase deficiency | R-HSA-9909438 | 0.420526 | 0.376 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 0.254869 | 0.594 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 0.221280 | 0.655 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 0.221280 | 0.655 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.221280 | 0.655 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 0.221280 | 0.655 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 0.193935 | 0.712 | 0 | 0 |
| RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) | R-HSA-8877330 | 0.284092 | 0.547 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 0.284092 | 0.547 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 0.187046 | 0.728 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.232435 | 0.634 | 0 | 0 |
| SHC-mediated cascade:FGFR1 | R-HSA-5654688 | 0.232435 | 0.634 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 0.232435 | 0.634 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 0.376516 | 0.424 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 0.376516 | 0.424 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 0.480445 | 0.318 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 0.480445 | 0.318 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 0.480445 | 0.318 | 0 | 0 |
| Drug-mediated inhibition of CDK4/CDK6 activity | R-HSA-9754119 | 0.480445 | 0.318 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 0.480445 | 0.318 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 0.252445 | 0.598 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 0.252445 | 0.598 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 0.252445 | 0.598 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 0.343110 | 0.465 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 0.343110 | 0.465 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 0.343110 | 0.465 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 0.316245 | 0.500 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 0.316245 | 0.500 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 0.414572 | 0.382 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 0.190090 | 0.721 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.190090 | 0.721 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.293604 | 0.532 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 0.153309 | 0.814 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 0.213668 | 0.670 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 0.372540 | 0.429 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 0.241031 | 0.618 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 0.226937 | 0.644 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.240503 | 0.619 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 0.162564 | 0.789 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 0.534171 | 0.272 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 0.534171 | 0.272 | 0 | 0 |
| FGFR1c and Klotho ligand binding and activation | R-HSA-190374 | 0.534171 | 0.272 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 0.534171 | 0.272 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 0.534171 | 0.272 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 0.534171 | 0.272 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.268437 | 0.571 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.278756 | 0.555 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 0.486921 | 0.313 | 0 | 0 |
| Signaling by activated point mutants of FGFR1 | R-HSA-1839122 | 0.486921 | 0.313 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 0.350038 | 0.456 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.350038 | 0.456 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.284474 | 0.546 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.284474 | 0.546 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 0.313168 | 0.504 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 0.406550 | 0.391 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 0.442068 | 0.355 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 0.461643 | 0.336 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 0.486356 | 0.313 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 0.486356 | 0.313 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 0.486356 | 0.313 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 0.486356 | 0.313 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 0.520945 | 0.283 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 0.520945 | 0.283 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 0.520945 | 0.283 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 0.582344 | 0.235 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 0.582344 | 0.235 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 0.582344 | 0.235 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 0.582344 | 0.235 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 0.582344 | 0.235 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 0.582344 | 0.235 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 0.582344 | 0.235 | 0 | 0 |
| Signaling by RNF43 mutants | R-HSA-5340588 | 0.582344 | 0.235 | 0 | 0 |
| Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS) | R-HSA-5619063 | 0.582344 | 0.235 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 0.371017 | 0.431 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 0.444678 | 0.352 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.444678 | 0.352 | 1 | 1 |
| HIV Transcription Initiation | R-HSA-167161 | 0.444678 | 0.352 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 0.444678 | 0.352 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 0.410078 | 0.387 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 0.463562 | 0.334 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 0.513287 | 0.290 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 0.513287 | 0.290 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 0.513287 | 0.290 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 0.513287 | 0.290 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 0.463737 | 0.334 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 0.463668 | 0.334 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 0.482275 | 0.317 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 0.553421 | 0.257 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 0.553421 | 0.257 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 0.553421 | 0.257 | 0 | 0 |
| SHC-mediated cascade:FGFR3 | R-HSA-5654704 | 0.539446 | 0.268 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 0.539446 | 0.268 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.539446 | 0.268 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.530546 | 0.275 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 0.530546 | 0.275 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 0.519054 | 0.285 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 0.519054 | 0.285 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 0.519054 | 0.285 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.537057 | 0.270 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.564778 | 0.248 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 0.564778 | 0.248 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 0.587462 | 0.231 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.587462 | 0.231 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 0.594810 | 0.226 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 0.593892 | 0.226 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 0.587462 | 0.231 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.367126 | 0.435 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.529787 | 0.276 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.357077 | 0.447 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 0.483647 | 0.315 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.348247 | 0.458 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.220516 | 0.657 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 0.272860 | 0.564 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 0.476292 | 0.322 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 0.401140 | 0.397 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.255563 | 0.593 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 0.461788 | 0.336 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.573970 | 0.241 | 0 | 0 |
| Crosslinking of collagen fibrils | R-HSA-2243919 | 0.486356 | 0.313 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 0.340656 | 0.468 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 0.257031 | 0.590 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 0.165324 | 0.782 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.458723 | 0.338 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.279267 | 0.554 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 0.430473 | 0.366 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 0.421744 | 0.375 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.427469 | 0.369 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.501014 | 0.300 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 0.486921 | 0.313 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 0.463562 | 0.334 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 0.552538 | 0.258 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.335784 | 0.474 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 0.270459 | 0.568 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.157531 | 0.803 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.183215 | 0.737 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 0.258526 | 0.587 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 0.553421 | 0.257 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.478521 | 0.320 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 0.226111 | 0.646 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 0.293604 | 0.532 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.376318 | 0.424 | 0 | 0 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.376318 | 0.424 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.376318 | 0.424 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 0.170917 | 0.767 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 0.170917 | 0.767 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 0.157961 | 0.801 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.349093 | 0.457 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 0.420968 | 0.376 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.444678 | 0.352 | 1 | 1 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 0.589239 | 0.230 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 0.435428 | 0.361 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 0.178230 | 0.749 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 0.297721 | 0.526 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 0.157961 | 0.801 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 0.313570 | 0.504 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 0.414572 | 0.382 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 0.372540 | 0.429 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 0.451426 | 0.345 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.234660 | 0.630 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 0.520945 | 0.283 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.462977 | 0.334 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.398755 | 0.399 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.568700 | 0.245 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.571223 | 0.243 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.370705 | 0.431 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 0.230249 | 0.638 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.571223 | 0.243 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.511252 | 0.291 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 0.273964 | 0.562 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 0.458723 | 0.338 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 0.157961 | 0.801 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.212906 | 0.672 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 0.232435 | 0.634 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 0.255785 | 0.592 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.279104 | 0.554 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 0.582344 | 0.235 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 0.504033 | 0.298 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 0.564778 | 0.248 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.305464 | 0.515 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 0.498979 | 0.302 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 0.498979 | 0.302 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.268437 | 0.571 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.237951 | 0.624 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 0.402561 | 0.395 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.425661 | 0.371 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.600004 | 0.222 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 0.548052 | 0.261 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.313513 | 0.504 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 0.501014 | 0.300 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.254945 | 0.594 | 1 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.319802 | 0.495 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 0.226111 | 0.646 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 0.425661 | 0.371 | 0 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.444678 | 0.352 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 0.552538 | 0.258 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 0.589202 | 0.230 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.594159 | 0.226 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 0.387306 | 0.412 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.532320 | 0.274 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 0.461643 | 0.336 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.523091 | 0.281 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 0.595827 | 0.225 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.156547 | 0.805 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.226510 | 0.645 | 0 | 0 |
| Abacavir transmembrane transport | R-HSA-2161517 | 0.257614 | 0.589 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 0.297721 | 0.526 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 0.267998 | 0.572 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 0.401706 | 0.396 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 0.357077 | 0.447 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 0.357077 | 0.447 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.197313 | 0.705 | 0 | 0 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.376318 | 0.424 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 0.520945 | 0.283 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.485049 | 0.314 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.524094 | 0.281 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.590393 | 0.229 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.502490 | 0.299 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.156547 | 0.805 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.203530 | 0.691 | 0 | 0 |
| Protein folding | R-HSA-391251 | 0.555868 | 0.255 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.399251 | 0.399 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 0.486356 | 0.313 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.389729 | 0.409 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.348247 | 0.458 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.333945 | 0.476 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 0.437875 | 0.359 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.551498 | 0.258 | 1 | 1 |
| NGF-stimulated transcription | R-HSA-9031628 | 0.271104 | 0.567 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 0.489800 | 0.310 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.547552 | 0.262 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.348908 | 0.457 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 0.292350 | 0.534 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 0.461643 | 0.336 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 0.376821 | 0.424 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 0.217599 | 0.662 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 0.480445 | 0.318 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 0.582344 | 0.235 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 0.606234 | 0.217 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.198717 | 0.702 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 0.287432 | 0.541 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.170256 | 0.769 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 0.257614 | 0.589 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 0.326839 | 0.486 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 0.326839 | 0.486 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 0.326839 | 0.486 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 0.326839 | 0.486 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.382473 | 0.417 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.406385 | 0.391 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 0.584306 | 0.233 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.577407 | 0.239 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.255930 | 0.592 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.405595 | 0.392 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 0.559247 | 0.252 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.319549 | 0.495 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.595903 | 0.225 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.309704 | 0.509 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 0.306826 | 0.513 | 1 | 1 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.560760 | 0.251 | 1 | 1 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.461788 | 0.336 | 1 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.266278 | 0.575 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.526462 | 0.279 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.526462 | 0.279 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.526462 | 0.279 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.606753 | 0.217 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 0.196063 | 0.708 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 0.279176 | 0.554 | 0 | 0 |
| Transport of connexins along the secretory pathway | R-HSA-190827 | 0.279176 | 0.554 | 0 | 0 |
| Inhibition of Host mRNA Processing and RNA Silencing | R-HSA-168315 | 0.279176 | 0.554 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 0.178230 | 0.749 | 0 | 0 |
| tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis | R-HSA-9708296 | 0.353702 | 0.451 | 0 | 0 |
| Signalling to ERK5 | R-HSA-198765 | 0.353702 | 0.451 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 0.177060 | 0.752 | 1 | 1 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 0.297721 | 0.526 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 0.420526 | 0.376 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.420526 | 0.376 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.193935 | 0.712 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 0.203530 | 0.691 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 0.376516 | 0.424 | 0 | 0 |
| Alanine metabolism | R-HSA-8964540 | 0.480445 | 0.318 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 0.480445 | 0.318 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 0.480445 | 0.318 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.159340 | 0.798 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 0.414572 | 0.382 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 0.401706 | 0.396 | 0 | 0 |
| Regulation of gene expression in early pancreatic precursor cells | R-HSA-210747 | 0.451426 | 0.345 | 0 | 0 |
| Trafficking of myristoylated proteins to the cilium | R-HSA-5624138 | 0.534171 | 0.272 | 0 | 0 |
| Reelin signalling pathway | R-HSA-8866376 | 0.534171 | 0.272 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.216186 | 0.665 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.350038 | 0.456 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 0.393867 | 0.405 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 0.486356 | 0.313 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 0.520945 | 0.283 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.582344 | 0.235 | 0 | 0 |
| Synthesis of dolichyl-phosphate mannose | R-HSA-162699 | 0.582344 | 0.235 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 0.582344 | 0.235 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.274866 | 0.561 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 0.553421 | 0.257 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.461788 | 0.336 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 0.530546 | 0.275 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 0.584306 | 0.233 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.559446 | 0.252 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 0.157961 | 0.801 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 0.356913 | 0.447 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.183415 | 0.737 | 1 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 0.574151 | 0.241 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.271104 | 0.567 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.333945 | 0.476 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 0.252445 | 0.598 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.420007 | 0.377 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 0.564778 | 0.248 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.502867 | 0.299 | 1 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 0.483647 | 0.315 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.532364 | 0.274 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.341824 | 0.466 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.605765 | 0.218 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 0.376516 | 0.424 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 0.255785 | 0.592 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 0.274633 | 0.561 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 0.530546 | 0.275 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.311151 | 0.507 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.158149 | 0.801 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.158149 | 0.801 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.482275 | 0.317 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 0.155771 | 0.808 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 0.414572 | 0.382 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 0.534171 | 0.272 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 0.399731 | 0.398 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 0.508035 | 0.294 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 0.539446 | 0.268 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 0.566847 | 0.247 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.437943 | 0.359 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.553468 | 0.257 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 0.303515 | 0.518 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 0.175596 | 0.755 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 0.552538 | 0.258 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.513287 | 0.290 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 0.191380 | 0.718 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 0.500783 | 0.300 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 0.526462 | 0.279 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 0.297721 | 0.526 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 0.221280 | 0.655 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 0.513287 | 0.290 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 0.495635 | 0.305 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.480021 | 0.319 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 0.313513 | 0.504 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 0.447525 | 0.349 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.197461 | 0.705 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.310497 | 0.508 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.291552 | 0.535 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.358657 | 0.445 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 0.362499 | 0.441 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 0.520945 | 0.283 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 0.277502 | 0.557 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 0.255785 | 0.592 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 0.370030 | 0.432 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 0.324035 | 0.489 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.420096 | 0.377 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 0.520945 | 0.283 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.246357 | 0.608 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.456910 | 0.340 | 1 | 1 |
| Signaling by KIT in disease | R-HSA-9669938 | 0.589239 | 0.230 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.261552 | 0.582 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.159340 | 0.798 | 0 | 0 |
| Oligomerization of connexins into connexons | R-HSA-190704 | 0.279176 | 0.554 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 0.257614 | 0.589 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 0.156199 | 0.806 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.171111 | 0.767 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 0.284092 | 0.547 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 0.244388 | 0.612 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 0.313570 | 0.504 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 0.401706 | 0.396 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 0.451426 | 0.345 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 0.451426 | 0.345 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 0.451426 | 0.345 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 0.486921 | 0.313 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 0.326839 | 0.486 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 0.462977 | 0.334 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 0.513287 | 0.290 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.435428 | 0.361 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 0.480963 | 0.318 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 0.537057 | 0.270 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.164418 | 0.784 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.159001 | 0.799 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 0.326839 | 0.486 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 0.284092 | 0.547 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 0.513287 | 0.290 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.582547 | 0.235 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.530760 | 0.275 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.376516 | 0.424 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.420968 | 0.376 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.587462 | 0.231 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.237407 | 0.625 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.235263 | 0.628 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 0.198795 | 0.702 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.289294 | 0.539 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 0.345236 | 0.462 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 0.316245 | 0.500 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 0.520945 | 0.283 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 0.293604 | 0.532 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 0.217599 | 0.662 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 0.353702 | 0.451 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 0.177060 | 0.752 | 0 | 0 |
| Anchoring fibril formation | R-HSA-2214320 | 0.226111 | 0.646 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 0.480445 | 0.318 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.252445 | 0.598 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 0.343110 | 0.465 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 0.401706 | 0.396 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 0.451426 | 0.345 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 0.534171 | 0.272 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 0.534171 | 0.272 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.420968 | 0.376 | 0 | 0 |
| Orexin and neuropeptides FF and QRFP bind to their respective receptors | R-HSA-389397 | 0.582344 | 0.235 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 0.513287 | 0.290 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 0.483647 | 0.315 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 0.595827 | 0.225 | 1 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 0.589202 | 0.230 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.480963 | 0.318 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 0.504033 | 0.298 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 0.252445 | 0.598 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.480963 | 0.318 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 0.486356 | 0.313 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 0.607761 | 0.216 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 0.221280 | 0.655 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 0.589239 | 0.230 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 0.178230 | 0.749 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 0.376516 | 0.424 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 0.376516 | 0.424 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 0.582344 | 0.235 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 0.582344 | 0.235 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 0.563100 | 0.249 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.409364 | 0.388 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 0.411417 | 0.386 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 0.524094 | 0.281 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.462977 | 0.334 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 0.171111 | 0.767 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 0.582344 | 0.235 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 0.462977 | 0.334 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 0.232435 | 0.634 | 1 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.486356 | 0.313 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 0.451426 | 0.345 | 0 | 0 |
| P2Y receptors | R-HSA-417957 | 0.584306 | 0.233 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 0.451426 | 0.345 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 0.335784 | 0.474 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 0.414572 | 0.382 | 0 | 0 |
| Replication of the SARS-CoV-1 genome | R-HSA-9682706 | 0.553421 | 0.257 | 0 | 0 |
| SARS-CoV-1 Genome Replication and Transcription | R-HSA-9679514 | 0.584306 | 0.233 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.612795 | 0.213 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 0.612795 | 0.213 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.612795 | 0.213 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 0.613582 | 0.212 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 0.613582 | 0.212 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 0.613582 | 0.212 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 0.613582 | 0.212 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 0.613582 | 0.212 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 0.613582 | 0.212 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 0.613582 | 0.212 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 0.613582 | 0.212 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.613582 | 0.212 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 0.615031 | 0.211 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 0.615031 | 0.211 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.616398 | 0.210 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.616420 | 0.210 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.618385 | 0.209 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 0.618385 | 0.209 | 1 | 1 |
| Signaling by FGFR2 | R-HSA-5654738 | 0.621131 | 0.207 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.621384 | 0.207 | 1 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 0.625538 | 0.204 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 0.625538 | 0.204 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 0.625538 | 0.204 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 0.625538 | 0.204 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 0.625538 | 0.204 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 0.625538 | 0.204 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 0.625538 | 0.204 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 0.625538 | 0.204 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 0.625538 | 0.204 | 0 | 0 |
| Lactose synthesis | R-HSA-5653890 | 0.625538 | 0.204 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 0.625538 | 0.204 | 0 | 0 |
| HDL clearance | R-HSA-8964011 | 0.625538 | 0.204 | 0 | 0 |
| CREB3 factors activate genes | R-HSA-8874211 | 0.625538 | 0.204 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 0.626766 | 0.203 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.630233 | 0.200 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 0.634612 | 0.197 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.634742 | 0.197 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 0.635425 | 0.197 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.635864 | 0.197 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.640027 | 0.194 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.640883 | 0.193 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 0.641251 | 0.193 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 0.641251 | 0.193 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 0.641251 | 0.193 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 0.641251 | 0.193 | 0 | 0 |
| Atorvastatin ADME | R-HSA-9754706 | 0.641251 | 0.193 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 0.643935 | 0.191 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 0.647137 | 0.189 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 0.653535 | 0.185 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 0.653535 | 0.185 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 0.653535 | 0.185 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 0.653535 | 0.185 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 0.653535 | 0.185 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.653535 | 0.185 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.653623 | 0.185 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 0.653623 | 0.185 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.655237 | 0.184 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.655237 | 0.184 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 0.657010 | 0.182 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 0.657114 | 0.182 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 0.657114 | 0.182 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 0.657114 | 0.182 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 0.657114 | 0.182 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.657114 | 0.182 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 0.657114 | 0.182 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 0.664267 | 0.178 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 0.664267 | 0.178 | 0 | 0 |
| Progressive trimming of alpha-1,2-linked mannose residues from Man9/8/7GlcNAc2 to produce Man5GlcNAc2 | R-HSA-964827 | 0.664267 | 0.178 | 0 | 0 |
| DAG1 core M1 glycosylations | R-HSA-8932506 | 0.664267 | 0.178 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to triglyceride lipolysis in adipose | R-HSA-9031528 | 0.664267 | 0.178 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 0.664267 | 0.178 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to gluconeogenesis | R-HSA-9632974 | 0.664267 | 0.178 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to limit cholesterol uptake | R-HSA-9031525 | 0.664267 | 0.178 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 0.664267 | 0.178 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 0.664267 | 0.178 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 0.664267 | 0.178 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 0.664267 | 0.178 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 0.664267 | 0.178 | 0 | 0 |
| Netrin mediated repulsion signals | R-HSA-418886 | 0.664267 | 0.178 | 0 | 0 |
| Defective HLCS causes multiple carboxylase deficiency | R-HSA-3371599 | 0.664267 | 0.178 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 0.664267 | 0.178 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 0.667333 | 0.176 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 0.667333 | 0.176 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 0.667333 | 0.176 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.667333 | 0.176 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 0.667333 | 0.176 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 0.667333 | 0.176 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 0.667333 | 0.176 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.667859 | 0.175 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.668718 | 0.175 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 0.669240 | 0.174 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 0.669305 | 0.174 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 0.669305 | 0.174 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 0.669305 | 0.174 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 0.671791 | 0.173 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 0.674065 | 0.171 | 1 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 0.676220 | 0.170 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 0.677857 | 0.169 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 0.677857 | 0.169 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 0.677857 | 0.169 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.685247 | 0.164 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 0.685247 | 0.164 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 0.685247 | 0.164 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 0.685247 | 0.164 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 0.685247 | 0.164 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 0.689371 | 0.162 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 0.689371 | 0.162 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 0.689371 | 0.162 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 0.689371 | 0.162 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 0.689371 | 0.162 | 1 | 1 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.690922 | 0.161 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.690922 | 0.161 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 0.691859 | 0.160 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 0.691859 | 0.160 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 0.691859 | 0.160 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 0.691859 | 0.160 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 0.691859 | 0.160 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 0.691859 | 0.160 | 0 | 0 |
| Replication of the SARS-CoV-2 genome | R-HSA-9694686 | 0.691859 | 0.160 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 0.697628 | 0.156 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.697628 | 0.156 | 0 | 0 |
| SHC-mediated cascade:FGFR2 | R-HSA-5654699 | 0.697656 | 0.156 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 0.697656 | 0.156 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 0.697656 | 0.156 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 0.697656 | 0.156 | 0 | 0 |
| Triglyceride biosynthesis | R-HSA-75109 | 0.697656 | 0.156 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 0.697656 | 0.156 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 0.697851 | 0.156 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 0.698993 | 0.156 | 0 | 0 |
| RSK activation | R-HSA-444257 | 0.698993 | 0.156 | 0 | 0 |
| DAG1 core M2 glycosylations | R-HSA-8932504 | 0.698993 | 0.156 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 0.698993 | 0.156 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 0.698993 | 0.156 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 0.698993 | 0.156 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 0.698993 | 0.156 | 0 | 0 |
| FGFR1b ligand binding and activation | R-HSA-190370 | 0.698993 | 0.156 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of keratinocytes | R-HSA-8939242 | 0.698993 | 0.156 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 0.698993 | 0.156 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 0.698993 | 0.156 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 0.698993 | 0.156 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 0.698993 | 0.156 | 0 | 0 |
| Regulation by c-FLIP | R-HSA-3371378 | 0.698993 | 0.156 | 0 | 0 |
| Fructose biosynthesis | R-HSA-5652227 | 0.698993 | 0.156 | 0 | 0 |
| BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members | R-HSA-111453 | 0.698993 | 0.156 | 0 | 0 |
| Dimerization of procaspase-8 | R-HSA-69416 | 0.698993 | 0.156 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 0.698993 | 0.156 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 0.698993 | 0.156 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 0.698993 | 0.156 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 0.698993 | 0.156 | 0 | 0 |
| Modulation by Mtb of host immune system | R-HSA-9637628 | 0.698993 | 0.156 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 0.698993 | 0.156 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.700660 | 0.154 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.701619 | 0.154 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.706272 | 0.151 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 0.706272 | 0.151 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.707716 | 0.150 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.708499 | 0.150 | 1 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 0.709086 | 0.149 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.712075 | 0.147 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 0.714873 | 0.146 | 0 | 0 |
| FGFR1 ligand binding and activation | R-HSA-190242 | 0.714873 | 0.146 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 0.714873 | 0.146 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 0.714873 | 0.146 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 0.714873 | 0.146 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 0.714873 | 0.146 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 0.714873 | 0.146 | 0 | 0 |
| Nucleotide-like (purinergic) receptors | R-HSA-418038 | 0.714873 | 0.146 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 0.714873 | 0.146 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.715543 | 0.145 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.715543 | 0.145 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 0.716517 | 0.145 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 0.716517 | 0.145 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 0.716517 | 0.145 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 0.716517 | 0.145 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 0.716517 | 0.145 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 0.716517 | 0.145 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 0.718213 | 0.144 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.719862 | 0.143 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.719862 | 0.143 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 0.722494 | 0.141 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 0.722494 | 0.141 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 0.722494 | 0.141 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 0.722494 | 0.141 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.723330 | 0.141 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.728884 | 0.137 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.729120 | 0.137 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 0.730128 | 0.137 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 0.730128 | 0.137 | 0 | 0 |
| CASP8 activity is inhibited | R-HSA-5218900 | 0.730128 | 0.137 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.730128 | 0.137 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 0.730128 | 0.137 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 0.730128 | 0.137 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 0.730128 | 0.137 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 0.730128 | 0.137 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 0.730128 | 0.137 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 0.730128 | 0.137 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 0.730128 | 0.137 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 0.730128 | 0.137 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 0.730128 | 0.137 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 0.730128 | 0.137 | 0 | 0 |
| Defects in biotin (Btn) metabolism | R-HSA-3323169 | 0.730128 | 0.137 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 0.730128 | 0.137 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.731268 | 0.136 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 0.731690 | 0.136 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 0.734452 | 0.134 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 0.734452 | 0.134 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 0.734452 | 0.134 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 0.736425 | 0.133 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 0.736425 | 0.133 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 0.736425 | 0.133 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 0.736425 | 0.133 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 0.736425 | 0.133 | 0 | 0 |
| SARS-CoV-2 Genome Replication and Transcription | R-HSA-9694682 | 0.736425 | 0.133 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 0.736425 | 0.133 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 0.738042 | 0.132 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 0.738042 | 0.132 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 0.738042 | 0.132 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.738042 | 0.132 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 0.738042 | 0.132 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.738363 | 0.132 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.740800 | 0.130 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.742462 | 0.129 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 0.743711 | 0.129 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 0.750214 | 0.125 | 0 | 0 |
| Kinesins | R-HSA-983189 | 0.750214 | 0.125 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 0.751478 | 0.124 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 0.751478 | 0.124 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 0.751478 | 0.124 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 0.752922 | 0.123 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 0.752922 | 0.123 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 0.752922 | 0.123 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 0.752922 | 0.123 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 0.752922 | 0.123 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.752922 | 0.123 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 0.752922 | 0.123 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 0.752922 | 0.123 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.752922 | 0.123 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 0.752922 | 0.123 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 0.753328 | 0.123 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 0.755800 | 0.122 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 0.756571 | 0.121 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 0.756571 | 0.121 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 0.756571 | 0.121 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.756571 | 0.121 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 0.756854 | 0.121 | 1 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.757018 | 0.121 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 0.758045 | 0.120 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 0.758045 | 0.120 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 0.758045 | 0.120 | 0 | 0 |
| Ion influx/efflux at host-pathogen interface | R-HSA-6803544 | 0.758045 | 0.120 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 0.758045 | 0.120 | 0 | 0 |
| Formation of intermediate mesoderm | R-HSA-9761174 | 0.758045 | 0.120 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 0.758045 | 0.120 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 0.758045 | 0.120 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 0.758045 | 0.120 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 0.758045 | 0.120 | 0 | 0 |
| Josephin domain DUBs | R-HSA-5689877 | 0.758045 | 0.120 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 0.762265 | 0.118 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.766104 | 0.116 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.766909 | 0.115 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 0.767142 | 0.115 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 0.767142 | 0.115 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 0.767616 | 0.115 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 0.767616 | 0.115 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 0.767616 | 0.115 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.767616 | 0.115 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.768065 | 0.115 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.768065 | 0.115 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 0.769767 | 0.114 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.771296 | 0.113 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.772942 | 0.112 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.773429 | 0.112 | 1 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.773880 | 0.111 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.773974 | 0.111 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.774370 | 0.111 | 1 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.774370 | 0.111 | 1 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 0.775371 | 0.110 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 0.775371 | 0.110 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 0.775371 | 0.110 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.776983 | 0.110 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.777255 | 0.109 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 0.778741 | 0.109 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 0.780713 | 0.108 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.782015 | 0.107 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.782015 | 0.107 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 0.782888 | 0.106 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 0.782888 | 0.106 | 0 | 0 |
| DAG1 core M3 glycosylations | R-HSA-8932505 | 0.783075 | 0.106 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 0.783075 | 0.106 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 0.783075 | 0.106 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 0.783075 | 0.106 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 0.783075 | 0.106 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 0.783075 | 0.106 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 0.783075 | 0.106 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 0.783075 | 0.106 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 0.783075 | 0.106 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.783969 | 0.106 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 0.785065 | 0.105 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 0.789048 | 0.103 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 0.792703 | 0.101 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 0.792888 | 0.101 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 0.792888 | 0.101 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 0.792888 | 0.101 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 0.792888 | 0.101 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 0.792888 | 0.101 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.793753 | 0.100 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 0.795825 | 0.099 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.795825 | 0.099 | 0 | 0 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 0.797321 | 0.098 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 0.797321 | 0.098 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 0.797321 | 0.098 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 0.797321 | 0.098 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 0.797808 | 0.098 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.799590 | 0.097 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.800936 | 0.096 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.801800 | 0.096 | 0 | 0 |
| Gamma-carboxylation of protein precursors | R-HSA-159740 | 0.805518 | 0.094 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 0.805518 | 0.094 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 0.805518 | 0.094 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 0.805518 | 0.094 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 0.805518 | 0.094 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 0.805518 | 0.094 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 0.805518 | 0.094 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 0.805518 | 0.094 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 0.805518 | 0.094 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 0.805518 | 0.094 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 0.805518 | 0.094 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 0.805518 | 0.094 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.805964 | 0.094 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 0.805964 | 0.094 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 0.805964 | 0.094 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 0.809187 | 0.092 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 0.809187 | 0.092 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 0.809187 | 0.092 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 0.809187 | 0.092 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 0.809187 | 0.092 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.809187 | 0.092 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 0.809187 | 0.092 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 0.809187 | 0.092 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 0.809187 | 0.092 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 0.809187 | 0.092 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.810669 | 0.091 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 0.810942 | 0.091 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.815736 | 0.088 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.816640 | 0.088 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 0.817673 | 0.087 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.820694 | 0.086 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.823781 | 0.084 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 0.824331 | 0.084 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 0.824331 | 0.084 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 0.824331 | 0.084 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 0.824331 | 0.084 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 0.824331 | 0.084 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 0.825639 | 0.083 | 0 | 0 |
| Gamma-carboxylation, transport, and amino-terminal cleavage of proteins | R-HSA-159854 | 0.825639 | 0.083 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 0.825639 | 0.083 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 0.825639 | 0.083 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 0.825639 | 0.083 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 0.825639 | 0.083 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 0.825639 | 0.083 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 0.825639 | 0.083 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.826002 | 0.083 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.828795 | 0.082 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 0.828795 | 0.082 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.834115 | 0.079 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 0.834740 | 0.078 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 0.835799 | 0.078 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 0.835866 | 0.078 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 0.835866 | 0.078 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 0.835984 | 0.078 | 1 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 0.835984 | 0.078 | 1 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 0.836650 | 0.077 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 0.838385 | 0.077 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 0.838385 | 0.077 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 0.838385 | 0.077 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 0.838385 | 0.077 | 0 | 0 |
| Assembly of active LPL and LIPC lipase complexes | R-HSA-8963889 | 0.838385 | 0.077 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 0.839347 | 0.076 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 0.839347 | 0.076 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 0.843680 | 0.074 | 0 | 0 |
| PDH complex synthesizes acetyl-CoA from PYR | R-HSA-9861559 | 0.843680 | 0.074 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 0.843680 | 0.074 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 0.843680 | 0.074 | 0 | 0 |
| Chylomicron remodeling | R-HSA-8963901 | 0.843680 | 0.074 | 0 | 0 |
| FGFR1c ligand binding and activation | R-HSA-190373 | 0.843680 | 0.074 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 0.843680 | 0.074 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 0.843680 | 0.074 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 0.843680 | 0.074 | 0 | 0 |
| Acyl chain remodeling of DAG and TAG | R-HSA-1482883 | 0.843680 | 0.074 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.844027 | 0.074 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 0.845139 | 0.073 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 0.845139 | 0.073 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.847230 | 0.072 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 0.847230 | 0.072 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.848790 | 0.071 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.849348 | 0.071 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 0.849348 | 0.071 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 0.851413 | 0.070 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 0.851413 | 0.070 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 0.851413 | 0.070 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 0.851413 | 0.070 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.851835 | 0.070 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 0.854036 | 0.069 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 0.857904 | 0.067 | 0 | 0 |
| SLC-mediated transport of organic cations | R-HSA-549127 | 0.857904 | 0.067 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.859825 | 0.066 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.859825 | 0.066 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 0.859855 | 0.066 | 0 | 0 |
| N-glycan trimming and elongation in the cis-Golgi | R-HSA-964739 | 0.859855 | 0.066 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 0.859855 | 0.066 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 0.859855 | 0.066 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 0.859855 | 0.066 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 0.859855 | 0.066 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 0.859855 | 0.066 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 0.859855 | 0.066 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 0.859855 | 0.066 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 0.859855 | 0.066 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 0.859855 | 0.066 | 0 | 0 |
| Ciprofloxacin ADME | R-HSA-9793528 | 0.859855 | 0.066 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 0.859855 | 0.066 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 0.859855 | 0.066 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 0.860048 | 0.065 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 0.862503 | 0.064 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 0.863477 | 0.064 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 0.863477 | 0.064 | 0 | 0 |
| Abacavir ADME | R-HSA-2161522 | 0.863477 | 0.064 | 0 | 0 |
| Attachment of bacteria to epithelial cells | R-HSA-9638630 | 0.863477 | 0.064 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 0.863477 | 0.064 | 0 | 0 |
| Translation | R-HSA-72766 | 0.865644 | 0.063 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.867918 | 0.062 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 0.867918 | 0.062 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.870554 | 0.060 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 0.874358 | 0.058 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 0.874358 | 0.058 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 0.874358 | 0.058 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 0.874358 | 0.058 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 0.874358 | 0.058 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.874358 | 0.058 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 0.874358 | 0.058 | 0 | 0 |
| Biotin transport and metabolism | R-HSA-196780 | 0.874358 | 0.058 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 0.874358 | 0.058 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 0.874358 | 0.058 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 0.874358 | 0.058 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 0.874635 | 0.058 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 0.874635 | 0.058 | 0 | 0 |
| Synthesis of PE | R-HSA-1483213 | 0.874635 | 0.058 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 0.874635 | 0.058 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.875265 | 0.058 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.876235 | 0.057 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 0.876235 | 0.057 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 0.876235 | 0.057 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.877304 | 0.057 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.878202 | 0.056 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 0.878202 | 0.056 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.878661 | 0.056 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.880034 | 0.056 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.884225 | 0.053 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 0.884225 | 0.053 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 0.884948 | 0.053 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.885462 | 0.053 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 0.886093 | 0.053 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 0.887360 | 0.052 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 0.887360 | 0.052 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 0.887360 | 0.052 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 0.887360 | 0.052 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 0.887360 | 0.052 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 0.887360 | 0.052 | 0 | 0 |
| Activation of the phototransduction cascade | R-HSA-2485179 | 0.887360 | 0.052 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 0.887360 | 0.052 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 0.887360 | 0.052 | 0 | 0 |
| Attachment and Entry | R-HSA-9678110 | 0.887360 | 0.052 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 0.887360 | 0.052 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.889206 | 0.051 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 0.891970 | 0.050 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.892622 | 0.049 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 0.894314 | 0.049 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.894314 | 0.049 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 0.894469 | 0.048 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 0.894469 | 0.048 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 0.894469 | 0.048 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 0.894469 | 0.048 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.895338 | 0.048 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.895338 | 0.048 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.895338 | 0.048 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.895338 | 0.048 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.895949 | 0.048 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.898864 | 0.046 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.898872 | 0.046 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 0.899017 | 0.046 | 0 | 0 |
| Glycine degradation | R-HSA-6783984 | 0.899017 | 0.046 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 0.899017 | 0.046 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 0.899017 | 0.046 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 0.899017 | 0.046 | 0 | 0 |
| Transcriptional regulation of testis differentiation | R-HSA-9690406 | 0.899017 | 0.046 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 0.899017 | 0.046 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 0.900589 | 0.045 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 0.901999 | 0.045 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 0.901999 | 0.045 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 0.901999 | 0.045 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 0.901999 | 0.045 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 0.903252 | 0.044 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.905267 | 0.043 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 0.909469 | 0.041 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 0.909469 | 0.041 | 0 | 0 |
| GDP-fucose biosynthesis | R-HSA-6787639 | 0.909469 | 0.041 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 0.909469 | 0.041 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 0.909469 | 0.041 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 0.911349 | 0.040 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.911349 | 0.040 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.911349 | 0.040 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 0.911349 | 0.040 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 0.911846 | 0.040 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.913534 | 0.039 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.914469 | 0.039 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 0.916427 | 0.038 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.916841 | 0.038 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 0.917763 | 0.037 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.918307 | 0.037 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 0.918807 | 0.037 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 0.918807 | 0.037 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 0.918839 | 0.037 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 0.918839 | 0.037 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.918839 | 0.037 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 0.918839 | 0.037 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 0.918839 | 0.037 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 0.918839 | 0.037 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 0.921651 | 0.035 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.921713 | 0.035 | 1 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.923322 | 0.035 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.925671 | 0.034 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 0.926584 | 0.033 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.926584 | 0.033 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 0.927241 | 0.033 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 0.927241 | 0.033 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 0.927241 | 0.033 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 0.927241 | 0.033 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 0.927241 | 0.033 | 0 | 0 |
| HDL remodeling | R-HSA-8964058 | 0.927241 | 0.033 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 0.927931 | 0.032 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 0.929284 | 0.032 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.930727 | 0.031 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.930944 | 0.031 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.931239 | 0.031 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 0.931239 | 0.031 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.931281 | 0.031 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.931863 | 0.031 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 0.931985 | 0.031 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 0.931985 | 0.031 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 0.931985 | 0.031 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 0.931985 | 0.031 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 0.934772 | 0.029 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 0.934772 | 0.029 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 0.934772 | 0.029 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 0.934772 | 0.029 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 0.935186 | 0.029 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 0.937788 | 0.028 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 0.937788 | 0.028 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 0.937788 | 0.028 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 0.937788 | 0.028 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.937788 | 0.028 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 0.937788 | 0.028 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.940598 | 0.027 | 1 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 0.941525 | 0.026 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 0.941525 | 0.026 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 0.941525 | 0.026 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 0.941525 | 0.026 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 0.941525 | 0.026 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 0.942328 | 0.026 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 0.942461 | 0.026 | 1 | 1 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 0.943120 | 0.025 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 0.943120 | 0.025 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 0.943120 | 0.025 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 0.945750 | 0.024 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 0.947327 | 0.024 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.947417 | 0.023 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.947417 | 0.023 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 0.947417 | 0.023 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 0.947579 | 0.023 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 0.947579 | 0.023 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 0.947579 | 0.023 | 0 | 0 |
| Molybdenum cofactor biosynthesis | R-HSA-947581 | 0.947579 | 0.023 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 0.947579 | 0.023 | 0 | 0 |
| Attachment and Entry | R-HSA-9694614 | 0.947579 | 0.023 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 0.947579 | 0.023 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 0.948014 | 0.023 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 0.948014 | 0.023 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 0.948914 | 0.023 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.951626 | 0.022 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 0.951913 | 0.021 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.952506 | 0.021 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 0.952506 | 0.021 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 0.952506 | 0.021 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 0.953006 | 0.021 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 0.953006 | 0.021 | 0 | 0 |
| WNT ligand biogenesis and trafficking | R-HSA-3238698 | 0.953006 | 0.021 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 0.953006 | 0.021 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 0.953006 | 0.021 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 0.953006 | 0.021 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 0.954019 | 0.020 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.954550 | 0.020 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.954550 | 0.020 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.954550 | 0.020 | 0 | 0 |
| Biofilm formation | R-HSA-9931953 | 0.956625 | 0.019 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.956856 | 0.019 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 0.956937 | 0.019 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.957066 | 0.019 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 0.957066 | 0.019 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.957441 | 0.019 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.957579 | 0.019 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 0.957872 | 0.019 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 0.957872 | 0.019 | 0 | 0 |
| Carnitine shuttle | R-HSA-200425 | 0.957872 | 0.019 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 0.957872 | 0.019 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 0.958237 | 0.019 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 0.958681 | 0.018 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.958681 | 0.018 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.959049 | 0.018 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 0.960012 | 0.018 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 0.960400 | 0.018 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 0.960400 | 0.018 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 0.961903 | 0.017 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.962035 | 0.017 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 0.962234 | 0.017 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 0.962234 | 0.017 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 0.962234 | 0.017 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 0.962390 | 0.017 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.963110 | 0.016 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 0.963859 | 0.016 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.963859 | 0.016 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 0.965682 | 0.015 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 0.966145 | 0.015 | 0 | 0 |
| Alpha-oxidation of phytanate | R-HSA-389599 | 0.966145 | 0.015 | 0 | 0 |
| Retinoid cycle disease events | R-HSA-2453864 | 0.966145 | 0.015 | 0 | 0 |
| Diseases of the neuronal system | R-HSA-9675143 | 0.966145 | 0.015 | 0 | 0 |
| Diseases associated with visual transduction | R-HSA-2474795 | 0.966145 | 0.015 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 0.967027 | 0.015 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 0.967027 | 0.015 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 0.967027 | 0.015 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 0.967027 | 0.015 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.967337 | 0.014 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 0.967650 | 0.014 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.968840 | 0.014 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 0.969651 | 0.013 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 0.969651 | 0.013 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 0.969651 | 0.013 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 0.969651 | 0.013 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 0.969651 | 0.013 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 0.969926 | 0.013 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 0.969926 | 0.013 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 0.969926 | 0.013 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.970025 | 0.013 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 0.970207 | 0.013 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.971635 | 0.012 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 0.972555 | 0.012 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.972579 | 0.012 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 0.972579 | 0.012 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 0.972794 | 0.012 | 0 | 0 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 0.972794 | 0.012 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 0.972794 | 0.012 | 0 | 0 |
| Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane | R-HSA-83936 | 0.972794 | 0.012 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 0.972794 | 0.012 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 0.972794 | 0.012 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.974175 | 0.011 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 0.974757 | 0.011 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.974797 | 0.011 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 0.975005 | 0.011 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 0.975612 | 0.011 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 0.975612 | 0.011 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 0.975612 | 0.011 | 0 | 0 |
| Prednisone ADME | R-HSA-9757110 | 0.975612 | 0.011 | 0 | 0 |
| Pyrimidine salvage | R-HSA-73614 | 0.975612 | 0.011 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 0.975612 | 0.011 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 0.975612 | 0.011 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 0.975871 | 0.011 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 0.976777 | 0.010 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 0.977222 | 0.010 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 0.977222 | 0.010 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 0.977222 | 0.010 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 0.977222 | 0.010 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 0.977234 | 0.010 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 0.977625 | 0.010 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 0.978138 | 0.010 | 0 | 0 |
| Regulation of pyruvate dehydrogenase (PDH) complex | R-HSA-204174 | 0.978138 | 0.010 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 0.978138 | 0.010 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 0.978138 | 0.010 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 0.978822 | 0.009 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 0.979825 | 0.009 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.979989 | 0.009 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.980453 | 0.009 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 0.981101 | 0.008 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 0.981101 | 0.008 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 0.981101 | 0.008 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 0.981335 | 0.008 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.981953 | 0.008 | 0 | 0 |
| Aspartate and asparagine metabolism | R-HSA-8963693 | 0.982433 | 0.008 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.982691 | 0.008 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.984040 | 0.007 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 0.984040 | 0.007 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 0.984253 | 0.007 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 0.984335 | 0.007 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 0.984335 | 0.007 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 0.984335 | 0.007 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 0.984628 | 0.007 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 0.984768 | 0.007 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.985489 | 0.006 | 0 | 0 |
| Glyoxylate metabolism and glycine degradation | R-HSA-389661 | 0.985743 | 0.006 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 0.985743 | 0.006 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.985754 | 0.006 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 0.985884 | 0.006 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 0.985884 | 0.006 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 0.986371 | 0.006 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.986789 | 0.006 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 0.987347 | 0.006 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 0.987347 | 0.006 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 0.988199 | 0.005 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.988199 | 0.005 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 0.988218 | 0.005 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 0.988658 | 0.005 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 0.988658 | 0.005 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 0.988658 | 0.005 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 0.988658 | 0.005 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 0.988658 | 0.005 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 0.989833 | 0.004 | 0 | 0 |
| Metabolism of ingested SeMet, Sec, MeSec into H2Se | R-HSA-2408508 | 0.989833 | 0.004 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 0.989833 | 0.004 | 0 | 0 |
| Defects in vitamin and cofactor metabolism | R-HSA-3296482 | 0.989833 | 0.004 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.990230 | 0.004 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 0.990241 | 0.004 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.990608 | 0.004 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.990775 | 0.004 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 0.990887 | 0.004 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 0.990887 | 0.004 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 0.990909 | 0.004 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 0.991061 | 0.004 | 1 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 0.991129 | 0.004 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 0.991666 | 0.004 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 0.991831 | 0.004 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 0.991831 | 0.004 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 0.991831 | 0.004 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 0.991831 | 0.004 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.992646 | 0.003 | 1 | 0 |
| Depurination | R-HSA-73927 | 0.992678 | 0.003 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 0.992836 | 0.003 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.993032 | 0.003 | 1 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.993112 | 0.003 | 1 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 0.993343 | 0.003 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 0.993437 | 0.003 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.993727 | 0.003 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.994117 | 0.003 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.994117 | 0.003 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 0.994117 | 0.003 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 0.994117 | 0.003 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 0.994117 | 0.003 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 0.994427 | 0.002 | 1 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 0.994508 | 0.002 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 0.994508 | 0.002 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.994530 | 0.002 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.994625 | 0.002 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 0.994727 | 0.002 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 0.994727 | 0.002 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 0.994727 | 0.002 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 0.994870 | 0.002 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 0.995013 | 0.002 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 0.995013 | 0.002 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 0.995013 | 0.002 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 0.995013 | 0.002 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 0.995013 | 0.002 | 0 | 0 |
| Heme biosynthesis | R-HSA-189451 | 0.995273 | 0.002 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 0.995763 | 0.002 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 0.995763 | 0.002 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 0.995763 | 0.002 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 0.995763 | 0.002 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 0.995880 | 0.002 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 0.996203 | 0.002 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 0.996563 | 0.001 | 0 | 0 |
| The canonical retinoid cycle in rods (twilight vision) | R-HSA-2453902 | 0.996949 | 0.001 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.997118 | 0.001 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 0.997266 | 0.001 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 0.997336 | 0.001 | 1 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 0.997473 | 0.001 | 0 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 0.997473 | 0.001 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 0.997519 | 0.001 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 0.997766 | 0.001 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.997801 | 0.001 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 0.997803 | 0.001 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 0.997958 | 0.001 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.998048 | 0.001 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.998183 | 0.001 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 0.998235 | 0.001 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 0.998292 | 0.001 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 0.998343 | 0.001 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 0.998418 | 0.001 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 0.998452 | 0.001 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.998800 | 0.001 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.998823 | 0.001 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 0.998861 | 0.000 | 0 | 0 |
| Digestion | R-HSA-8935690 | 0.999085 | 0.000 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 0.999117 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 0.999144 | 0.000 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 0.999180 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 0.999204 | 0.000 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.999208 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.999331 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 0.999471 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 0.999575 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 0.999575 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 0.999608 | 0.000 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 0.999619 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 0.999692 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 0.999711 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 0.999722 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 0.999726 | 0.000 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.999726 | 0.000 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 0.999766 | 0.000 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 0.999766 | 0.000 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 0.999823 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 0.999823 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 0.999834 | 0.000 | 1 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.999841 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 0.999842 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 0.999844 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 0.999858 | 0.000 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.999865 | 0.000 | 0 | 0 |
| Transport of vitamins, nucleosides, and related molecules | R-HSA-425397 | 0.999873 | 0.000 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 0.999873 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 0.999886 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 0.999896 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 0.999915 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 0.999916 | 0.000 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 0.999918 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 0.999920 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 0.999929 | 0.000 | 1 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 0.999941 | 0.000 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 0.999941 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 0.999949 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 0.999956 | 0.000 | 1 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 0.999958 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 0.999975 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.999978 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 0.999985 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 0.999988 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 0.999990 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 0.999991 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 0.999992 | 0.000 | 1 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 0.999992 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 0.999994 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 0.999995 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 0.999996 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 0.999997 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 0.999997 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 0.999998 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 0.999998 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 0.999999 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 0.999999 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 0.999999 | 0.000 | 1 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 0.999999 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 0.999999 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 0.999999 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 0.999999 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 1.000000 | 0.000 | 1 | 0 |
| Keratinization | R-HSA-6805567 | 1.000000 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000 | 0.000 | 1 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000 | 0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000 | -0.000 | 1 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000 | -0.000 | 1 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000 | -0.000 | 0 | 0 |